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ABSTRACT 
 
Infectious disease remains one of the leading causes of morbidity and mortality 
worldwide. Many bacteria that cause disease have the capacity to enter into eukaryotic 
cells such as epithelial cells and tissue macrophages. Gaining access into the 
intracellular environment is one of the most critical steps in their survival and/or in 
pathogenesis. The entry mechanisms employed by these organisms vary considerably, 
but most mechanisms involve sabotaging and manipulating host cell functions. Invasion 
of epithelial cells involves triggering host signal transduction mechanisms to induce 
cytoskeleton rearrangement, thereby facilitating bacterial uptake. My work focuses on 
understanding the molecular mechanisms employed by bacterial pathogen Listeria 
monocytogenes and Chlamydia trachomatis to gain access into the host cells in order to 
cause the disease. 
In first part of my thesis I investigated the mechanism of Listeria monocytogenes 
entry. Listeria, a facultative intracellular organism, is responsible for causing meningitis, 
septicemia, gastroenteritis and abortions. Critical for Listeria virulence is its ability to get 
internalized, replicates and spread into adjacent host cells. One of the pathways of 
Listeria internalization into mammalian cells is promoted by binding of its surface protein 
Internalin B (InlB) to host receptor MET. Studies done in the past demonstrated a critical 
role of host type IA Phosphoinositide (PI) 3-kinase in controlling cytoskeleton 
rearrangement and entry of Listeria downstream of MET. An important unresolved 
question was how activation of PI3K results in cytoskeleton rearrangements that 
promote Listeria entry.  In this work, we identified 9 host signaling molecules, that 
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includes Rab 5c, SWAP 70, GIT1, PDK1, mTor, ARAP2, ARNO, DAPP1 & PKC-δ, acting 
downstream of type IA Phosphoinositide (PI) 3-kinase to regulate changes in host 
cytoskeleton to cause Listeria entry. 
Second part of my thesis involved studying the functions of chlamydial effector 
protein Tarp in its invasion. Infection caused by Chlamydia Trachomatis is the most 
common sexually transmitted disease resulting in uro-genital diseases, LGV, ectopic 
pregnancy and infertility. It is also responsible for causing trachoma, the leading cause 
of preventable blindness in third world countries. Being an obligate intracellular 
pathogen, gaining access into intracellular environment is the most critical step in 
lifecycle and pathogenesis of Chlamydia. Previous studies demonstrate the role of both 
chlamydial and host actin nucleators, Tarp and Arp2/3 complex respectively, in 
mediating Chlamydial entry into non-phagocytic cells. But the molecular details of these 
processes were not well understood. In this study, we demonstrate novel function of 
Tarp protein to form actin bundles by its ability to bind filamentous actin through newly 
identified FAB domains. And we also provide bio-chemical evidence that Tarp and 
Arp2/3 complex works in conjunction to cause changes in host cytoskeleton that 
effectively culminate into bacterial uptake by host cells. 
Overall, this research was a significant step in enhancing our understanding, at a 
molecular level, to pathogenesis of infections caused by Listeria monocytogenes and 
Chlamydia trachomatis. 
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CHAPTER ONE: INTRODUCTION 
 
The following chapter will introduce important concepts in the bacterial invasion of 
host cells. The broad focus of this thesis was to understand the subversion of host 
pathways by intracellular pathogens Listeria monocytogenes and Chlamydia 
trachomatis. This work was done to enhance our understanding of host-pathogen 
interaction with an ultimate goal to develop new preventive strategies to target these 
bacteria at the point of their entry.  
1.1 Actin Cytoskeleton: A Key to Bacterial Invasion 
 
Cytoskeleton dynamics plays a key role in many physiologic processes including 
cell migration and motility, chemotaxis, migration during embryogenesis endocytosis 
and phagocytosis [1-3]. It is no surprise that bacteria have evolved mechanisms to 
hijack cytoskeletal machinery for their own benefits. The main components of the 
cytoskeleton include microfilaments (7nm), intermediate filaments (10nm) and 
microtubules (25nm). The exploitation of microtubules has been reported only in case of 
a few organisms like entero-invasive E. coli, C. jejuni, C. freundii [4, 5]. In contrast, the 
subversion of actin filaments seems to be the common mechanism used by many 
pathogens. For example, entero-hemorrhagic E. coli, an extracellular pathogen 
modulate actin machinery to attach to host cells [6]. Intracellular bacteria like Rickettsia, 
Chlamydia and Listeria exploit the actin cytoskeleton for invasion as well as for intra and 
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intercellular movement [7, 8]. Below I will discuss the actin cytoskeletal machinery and 
how actin polymerization is regulated. 
1.1.1 Actin and Actin Nucleation Machinery 
 1.1.1.1 Actin and Actin Turnover 
First isolated in 1945 by Sczent Gyori, actin is a ~42 kDa ATP binding protein 
found in abundance in all eukaryotic cell types. It exists in two interchangeable forms, a 
monomeric G-actin and structurally twisted helical filaments (F-actin) [9, 10]. Actin 
filaments are formed by reversible polymerization of monomers by a process which 
involves ATP hydrolysis and release of inorganic phosphate. The two ends of actin 
filaments are biochemically distinct in that the addition of monomers is more favorable 
at one end [11, 12]. This fast growing end is called the barbed (+) end, whereas the 
opposite slow growing end is called as pointed (-) end. Actin dynamics is tightly 
regulated by monomer and filament binding proteins that control the free pool of 
monomers, regulate the polymerization process, organize the filaments into networks 
and also control filament depolymerization for recycling of monomers [13]. Profilin and 
cofilin are the two main actin binding proteins responsible for polarized growth of 
filaments [13, 14]. Profilin guides the ATP bound G-actin to the barbed end and favors 
the growth of filaments, whereas cofilin enhances dissociation of ADP bound G-actin 
from the pointed end to restrict the length of filaments [15, 16]. In unstimulated 
conditions the barbed ends are blocked by capping proteins to prevent unnecessary 
growth of filaments. Formation of new filaments depends on the presence of free 
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barbed ends that acts as template for addition of new monomers. Free barbed ends can 
be created by three distinct mechanisms; uncapping of barbed ends, severing of 
filaments or de novo nucleation [17, 18]. Nucleation is the rate limiting step in 
generation of new filamentous from actin monomers. It involves bridging of 3 monomers 
together to form a seed that favors addition of new monomers [19]. Spontaneous 
nucleation is kinetically unfavorable and requires the presence of free monomers above 
the certain critical concentration of actin [20, 21]. Thus the nucleation step is usually 
regulated by other cellular proteins called actin nucleators, which will be discussed 
below. 
1.1.1.2 The Arp2/3 Complex 
There are three different actin nucleating proteins identified so far in eukaryotic 
cells: the Arp2/3 complexes, formins and spire-like actin nucleators [22-24]. Each 
nucleator uses a distinct mechanism to nucleate actin. While formins and spire-like actin 
nucleators bind actin monomers and form linear filaments, the Arp2/3 complex bind 
monomers and preexisting filaments to promote actins branching [25-29].  
The Arp2/3 complex is the most extensively studied actin nucleating protein 
because it plays such a central role in regulating actin nucleation. The Arp2/3 complex 
is a multimeric complex of 7 subunits including Arp2, Arp3, p16, p20, p21, p34 and p40 
[24, 30]. The Arp2 and Arp3 subunits share structural similarity to actin. The other 
subunits provide structural conformation that allow binding to filamentous actin [25, 26]. 
The Arp2/3 complex by itself cannot nucleate actin and requires prior activation by 
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nucleation promoting factors (NPF) [31-33]. Activation of the Arp2/3 complex results in 
conformational change such that it binds to preexisting actin filaments via its „p‟ subunits 
[34]. And Arp2 and Arp3 subunits mimic the barbed end of an actin filament which along 
with NPF promote actin nucleation [35]. This activity generates a new actin filament that 
forms a 70 degree branching pattern over a pre-existing filament [36]. 
1.1.1.3 Nucleation Promoting Factors 
There are two known NPF family of proteins in eukaryotes that can directly 
activate the Arp2/3 complex which includes Wiskott- Aldrich syndrome protein (WASP) 
and Wasp- family verproline -homologus protein (WAVE) [37]. The WASP family 
includes two members (hematopoietic WASP and ubiquitously expressed N-WASP), 
whereas the WAVE family includes three members of which WAVE1 and WAVE3 are 
mainly neuronal and WAVE 2 is universally expressed. WASP and WAVE naturally 
exist in auto inhibitory conformations that do not favor interaction with the Arp2/3 
complex [37]. Rho family GTPases interact with WASP and WAVE to induce 
conformational changes resulting in their activation [38, 39]. Both WASP and WAVE 
share certain common domains including the WCA domain, the Pleckstrin Homology 
domain (PH) and the proline rich domain (PRD) [37]. In an active state WASP/WAVE, 
via its WCA domain, simultaneously binds to G-actin and the Arp2/3 complex and 
promotes actin nucleation. The PH domain interacts with phosphatidylinositol 
(PI(3,4,5)P3 in WAVE and PI(4,5)P2 in WASP) which results in the recruitment of 
cytoplasmic WASP and WAVE complexes to plasma membrane [40, 41]. The PRD 
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domain binds to profilin that aids in supplying actin monomers [37]. Together, this 
results in the formation of actin filaments which alters the shape of the plasma 
membrane. WASP/Arp2/3 complex activity mainly results in fine extensions of plasma 
membrane called filopodia [42], whereas WAVE2/Arp2/3 complex activity is responsible 
for causing dramatic rearrangements of plasma membrane called lamellopodia [43, 44]. 
1.1.1.4 Rho Family GTPases 
Rho family GTPases belong to a family of small GTP/GDP binding proteins that 
act as molecular switches in regulating appropriate cellular responses to extracellular 
stimuli [45]. Like other GTP binding proteins, Rho family GTPases harbor a GTP/GDP 
binding domain and also possess GTPase activity [45]. They alternate between active 
GTP bound and inactive GDP bound forms depending upon the upstream stimulus. 
When in an active conformation, these GTPases influence the cytoskeleton network by 
regulating the activity of nucleation promoting factors such as WASP and WAVE [45]. 
Cdc42 binds directly to the CRIB domain of N-WASP and Rac and, using several 
adaptor proteins, interacts indirectly with the PRD domain of WAVE-2 to facilitate an 
interaction with the Arp2/3 complex [37]. 
The activity of Cdc42/Rac is regulated by three groups of proteins: including 
GTPase activating proteins (GAPs), GDP dissociation inhibitors (GDIs), and Guanine 
nucleotide exchange factors (GEFs). GAP promotes the intrinsic activity of Rho 
GTPases to hydrolyze GTP, and GDI prevents GDP-GTP exchange by inhibiting the 
Rho GTPase activity [46, 47]. GEF facilitates the removal of GDP from Rho GTPases, 
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thereby promoting GTP binding due to GTP being present in the cytoplasm at a higher 
concentration than GDP [48]. Regulation of Rho GTPases is very complex as more than 
100 regulatory proteins are present in eukaryotic cells, with each regulating one to 
several Rho GTPases. To add more complexity, different regulators can be stimulated 
by several upstream signaling proteins in response to many different extracellular 
stimuli. Elucidating these complex arrays of signaling events has been a major 
challenge in every field of molecular research including cellular microbiology. 
1.1.2 Bacterial Entry: Zipper Vs Trigger Mechanism 
The human body is composed of two types of cell: phagocytic and non-
phagocytic cells. Phagocytic cells such as neutrophils, macrophages, dendritic cells and 
mast cells have the capacity to uptake large particles like bacteria. These cells play a 
key role in controlling bacterial infections by secretion of inflammatory mediators and 
antigen presentation [49-53]. A few intracellular bacteria like Mycobacterium spp, 
Brucella spp, Listeria, spp, and Legionella spp have evolved mechanisms to survive and 
replicate within phagocytes [54]. For most bacterial pathogens, the phagocytic 
environment is not a safe zone. Most pathogens prefer to invade non-phagocytic cells 
like epithelial cells, endothelial cells and fibroblasts. Unlike professional phagocytes, 
these cells lack the capacity to uptake large particles like bacteria. Thus, many 
intracellular organisms induce their own uptake in these non-phagocytic cell types by a 
process called “induced phagocytosis”. In 1995, Swanson and Baer , proposed the 
concept of “Zipper and Trigger mechanisms” of bacterial entry into non-phagocytic cells. 
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The main difference between the two mechanisms is that the former is stimulated from 
outside, whereas the latter is triggered from inside the host cells. The Zipper 
mechanism is widely used by gram positive and negative organisms, whereas the 
trigger mechanism is exclusively seen in entry of gram negative organisms. 
1.1.2.1 The Zipper Mechanism 
The zipper mechanism is a process that involves binding of bacterial surface 
proteins (adhesins) to host cell surface receptors. Each adhesin has the propensity to 
interact only with a specific type of host receptor, an interaction responsible for host 
specificity, tissue tropism and pathogenesis.  Such interactions cause activation of host 
cell surface receptors resulting in initiation of downstream signaling pathways. These 
signaling pathways in turn activate actin nucleation machinery to cause changes that 
favor uptake of bacteria (see figure 1). In the zipper mechanism, the cytoskeletal 
changes do not involve major remodeling of the host cell surface; The plasma 
membrane remains in close association with the invading bacterium [55]. Many bacterial 
adhesins and their specific host receptors have been identified that promote uptake of 
an organism via the zipper mechanism. For example, Yersinia enterocolitica uses its 
surface protein invasin to bind and activate β-1 integrin whereas Neisseria gonorrhea 
uses OpaA to bind to heparan sulfate proteoglycan of the syndecan family to promote 
its own invasion [56-58]. Listeria monocytogenes uses InlA and InlB which bind E-
cadherin and Met receptors present on the surface of many human cell types [59-61]. 
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1.1.2.2 The Trigger Mechanism 
The trigger mechanism is more complex and involves dramatic rearrangement of 
the host cell surface membrane in the form of filopodia and lamellopodia which promote 
passive uptake of organisms by a mechanism similar to macropinocytosis. Such 
process involves delivery of secreted bacterial effector proteins into the host cytoplasm 
using a needle-like Type 3 secretion system. These effector proteins modulate the 
cytoskeleton to favor bacterial uptake [55]. Effector proteins display a diverse range of 
functional capacity (See figure 1). For example, Shigella, which causes inflammatory 
diarrhea, delivers the effector protein IpaC which mimics the activity of the Rho GTPase 
cdc42 to mediate N-Wasp/Arp2/3 dependent actin polymerization [62]. RickA of R. 
coronii mimics a nucleation promoting factor (NPF) and directly activates Arp2/3 
complex [63]. Recently, certain effector proteins like SipC of Salmonella and Tarp of 
Chlamydia were discovered to directly bind and nucleate actin to cause actin 
polymerization [64, 65]. 
1.2 Listeria monocytogenes 
 
1.2.1 Background and Taxonomy 
Listeria monocytogenes is a gram positive facultative anaerobic organism and is 
ubiquitously found in nature. Although the natural habitat of Listeria is believed to be 
decomposing vegetation, it is abundantly found in a variety of environmental sources 
including soil, sewage, silage, water and decaying dead animals [66]. It belongs to the 
genus Listeria which currently includes 8 other species: L. ivanovii, L. seeligeri, L. 
9 
 
innuocua, L. welshimeri, L. grayi, L. marthii, L. rocourtiae and L. weihemstephanensis. 
The genetic makeup of Listeria is well adapted to a saprophytic life style. It harbors 
multiple genes to facilitate the use of a variety of organic compounds as a source of 
carbon [67]. It expresses flagella which confers swimming motility for accessing nutrient 
sources [68]. Although Listeria does not form spores, it is very sturdy and survives a 
variety of environmental stresses including shifts in temperature, pH, osmolarity and 
oxidative stress [66].  
While the majority of species in the genus Listeria are harmless saprophytes, L. 
monocytogenes, L. ivanovii and L. seeligeri are also potential pathogens. A Wide variety 
of warm blooded hosts are known to be the targets of Listeria including ruminants, 
sheep, goats, pigs, dogs, ferrets, raccoons, foxes, rats, gerbils, voles, hamsters, cats, 
horses, eagles and humans [69]. Once inside the infected host, Listeria can live either 
as a non-pathogenic extracellular bacterium or invade the tissues and become a deadly 
pathogen [69]. Interestingly, a comparative genomic analysis and evolutionary study 
has indicated that the loss of virulent genes from pathogenic species is responsible for 
evolution of non-pathogenic species. The Genus Listeria thus harbors the species of  
microorganisms that have evolved from a pathogenic to saprophytic life style. 
1.2.2 Epidemiology, Infection and Pathogenesis 
L. monocytogenes is mainly responsible for the vast majority of Listeria infections 
in humans, with only a few isolated reports of confirmed infections by L. ivanovii and L. 
seeligeri. Serovars 1/2a, 1/2b and 4b of L. monocytogenes cause more than 90% of all 
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human infections [70]. The Infectious disease caused by L. monocytogenes is known as 
listeriosis. It is one of the deadliest food-borne infections carrying a net mortality risk of 
approximately 30% [71]. It is responsible for causing nearly 2500 deaths per year in 
USA [72]. The transmission usually occurs via the oral route by consuming  
contaminated food. Infections can occur sporadically or can result in outbreaks affecting 
many people. The majority of the outbreaks are usually due to contamination of ready to 
eat (RTE) packaged foods. Milk and meat products such as salads, meat sandwiches, 
cheeses, etc. are the main sources of infection [73]. Outbreaks of listeriosis are 
evidently increasing over the last few decades because of the increase in industrialized 
farming and food processing. Contamination of processed food by L. monocytogenes 
has resulted in many food recalls in the past few years [73]. Recently, listeriosis has 
emerged as a disease of such a financial and public health concern that the FDA has 
approved a listeriocidal drug (a bacteriophage) as an food additive [74].  
Host risk factors play a critical role in the development of disease following 
exposure to L. monocytogenes. The disease usually manifests in individuals with 
defects in T-cell mediated immunity.[71]. Patients who are at a higher risk include 
newborns, pregnant women, and the elderly. The disease usually manifests in adults 
with severe debilitating conditions like cancer, leukemia and lymphomas, Diabetes 
mellitus, chronic kidney or liver disease, as well as those undergoing 
immunosuppressive therapies. The current epidemic of HIV and cancers are also 
responsible for an upward trend observed in the incidence of listeriosis [71].  
11 
 
Pathogenesis of the disease caused by L. monocytogenes is a multi-step 
process. It involves : 1) the oral transmission and colonization of the gastro-intestinal 
tract; 2) invasion through the intestinal epithelium, 3) replication in the liver followed and 
4) the systemic spread to other organs [71](see figure 2). The clinical manifestation of 
listeriosis depends on the organ system involved. The infection in early pregnancy can 
lead to placentitis, chorioamnionitis and abortion. In late pregnancy, the infection usually 
gets transmitted to the fetus and causes neonatal sepsis. In fact, it is one of the three 
leading causes of neonatal sepsis, along with group B streptococci and E. coli.  
Listeriosis usually manifests in adults as gastroenteritis and/or infections of the central 
nervous system leading to meningitis, encephalitis and meningo-encephalitis. Very 
rarely, it may also cause granulomatous hepatitis, granulomatous skin lesion and 
infections of other organs [75]. 
1.2.3 Intracellular Lifecycle of L. Monocytogenes 
L. monocytogenes has the capacity to infect a wide variety of tissue specific host 
cells including macrophages, epithelial cells, endothelial cells, hepatocytes, fibroblasts, 
neurons and placental tissue [76-81]. Regardless of the cell type it parasitizes, the 
intracellular life cycle of listeria shares certain common characteristics (see figure 3). 
1.2.3.1 Invasion 
Invasion of the host cell is a critical steps in the pathogenesis of disease caused 
by L. monocytogenes. In order to enter the host cell, Listeria uses surface proteins such 
as Internalin A and Internalin B [76].  These proteins recognize the host cell surface 
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receptors and attach to them. Such interactions trigger the activation of host signal 
transduction pathways that cause changes to the host cytoskeleton that favor entry of 
listeria.  This mechanism of entry is known as the zipper mechanism. It involves 
progressive wrapping of a bacterium by the host plasma membrane. The final product of 
this process is the engulfment by the host cell of a bacteria enclosed within a membrane 
bound vacuole [82].  
1.2.3.2 Escape 
Once inside the host cell, Listeria escape from the vacuole to enter the 
cytoplasm. Doing so is critical for Listeria to survive because overtime the vacuole will 
fuse with lysozomes which are rich in degradative enzymes and that would kill the 
bacterium [83-86]. In order to disrupt the vacuole, Listeria uses the enzymes 
Listeriolysin O (LLO) and Phospholipase C (PLcA and PLcB)[81, 86-89]. These 
enzymes insert into the vacuolar membrane, forming pores that provides pathways for 
Listeria to enter into the cytoplasm.  LLO  a is very potent enzyme and can potentially 
harm the host cells by disrupting the host cell membrane and other membrane bound 
organelles, though it is rapidly inactivated following its exposure to host cytoplasm. 
Thus, its activity is spatially and temporally restricted to endosomes containing Listeria. 
[90-94] (see figure 3).   
1.2.3.3 Replication and Dissemination 
Following its entry into a nutrient rich cytoplasmic environment, Listeria not only 
replicates, but also hijacks the actin cytoskeleton machinery to acquire intracellular 
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motility. This is essential because it helps Listeria to spread directly from cell to cell, 
thus avoiding the necessity of getting exposed to the hostile extracellular environment. 
To achieve such capabilities Listeria employs two proteins: Act A and Internalin C. Act A 
is a surface protein that Listeria expresses within the cytoplasmic environment. It 
harbors a domain that directly binds to monomeric actin [95-98]. Act A functions as a 
nucleation promoting factor and along with the host actin nucleator, the Arp2/3 complex, 
an “actin comet tail” that propels the bacterium, granting it motility[31] . Obviously, such 
activity suggests that Act A is localized to one pole of the bacterium. The polarization of 
Act A occurs during the active phase of intracellular replication [7, 89, 95, 99-101].  
Another protein that favors intracellular dissemination is Internalin C (InlC). Listeria 
secretes InlC protein in the host cytoplasm. InlC acts on the intracellular junctions to 
perturb the adherent junctions, thereby enhancing the ability of motile bacteria to form a 
protrusion into an adjacent recipient cell [102]. These protrusions are called 
“listeriopods”. After listeriopods are completely taken up by the recipient cells, LLO and 
PLCB disrupts the membrane to release the Listeria back into the cytoplasm. [103, 104].  
This allows a new replication cycle to begin. Such repetitions of replication and cell to 
cell dissemination are critical for pathogenesis of listeria infections and disruption at any 
stage may compromise pathogenicity [105]. 
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1.2.4 Invasion into Mammalian Cells: The Zipper Mechanism 
1.2.4.1 Attachment 
Listeria can invade both phagocytic cells including neutrophils, tissue 
macrophages, and non-phagocytic cells including epithelial cells, endothelial cells, 
hepatocytes and trophoblasts [71, 106, 107]. The initial step in entry is the attachment 
of Listeria surface adhesins to the host cell surface receptors. Listeria express a variety 
of putative surface adhesins including  Internalin A (InlA), Internalin B (InlB), InlJ, Ami, 
Vip, p60, LAP, FbpA and ActA. But only InlA and InlB were found to be critical for 
invasion. Other proteins have characteristic functions or expression patterns which 
suggest that they have evolved for the purpose other than invasion. Internalin A (InlA) 
and Internalin B (InlB) binds to the host surface receptors E-cadherin and MET tyrosine 
kinase receptors, respectively [60, 61]. The mode of entry depends on the type of 
receptor present on the specific host cell. In intestinal epithelium (which represent the 
initial entry point of Listeria), internalization depends on InlA/E-Cadherin interaction [60, 
108]. In most other tissues including hepatocytes (the predominant site of bacterial 
replication) the entry likely depends on the InlB/Met receptor interaction [107]. InlA/E-
cadherin or InlB/MET interactions lead to the activation of signal transduction pathways 
that produce changes to the cytoskeleton that lead to engulfment of bacteria 
1.2.4.2 Internalin Family and InlB 
InlA and InlB are the only known virulence genes in L. monocytogenes that are 
involved in its entry into the eukaryotic host cell [106, 109]. They were first identified in a 
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genetic screen using transposon induced listeria mutants to test for their reduced 
invasiveness capabilities in Caco2 cell lines [76].  As InlAB gene locus was found to be 
critical for internalization of listeria, it was named Internalin. Multiple studies later 
confirmed the role of InlA and InlB in entry by employing several techniques such as 
genetic manipulations that rendered L. monocytogenes less invasive, confering 
invasiveness to non-invasive species or in-vitro assays using purified recombinant InlA 
and InlB proteins [76, 78, 110-114].  
Four other internalin gene loci were subsequently identified in the L.  
Monocytogenes genome. These loci encode for seven Internalin homologs which 
includes InlC, InlC2, InlD, InlE, InlF, InlG and InlH (See figure 4). The studies aimed to 
identify the functions of these Internalins failed to demonstrate their role in entry [111, 
115, 116]. However, InlC was later found to function at intracellular junctions and helps 
in cell to cell dissemination of L. monocytogenes [102]. The genes for InlC2, InlD, InlF, 
and InlG have also been identified in non-invasive species like L. innocua, suggesting 
that these are non-virulent genes. However the exact role of these internalins in Listeria 
biology and pathogenesis has not yet been determined [71, 76]. 
InlB structure: InlB is a 67 kDa protein which consists of a polypeptide having 
630 amino acids. The N-terminal half of InlB harbors a signal peptide, the LRR domain 
and the IR region, whereas the C-terminal half harbors a GW module having three 
repeats of a GW domain (see figure 4) [117, 118]. 
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The LRR domain is the most conserved domain of InlB. It consists of 7 leucine 
rich repeats of 22 amino acids having leucine placed at certain fixed positions (See 
figure 3) [119]. On X-Ray crystallography, each LRR repeat consists of a short β-strand 
followed by a helical region and a loop [120, 121]. Together this imparts a horseshoe 
shape to the LRR domain that has a concave and a convex surface [118]. The LRR 
domain interacts with the Met receptor through its concave surface [122, 123]. This 
domain is sufficient and necessary for the activation of the Met receptor and 
internalization of Listeria, although the potency of LRR activity alone is less than that of 
full length InlB [61]. Thus the other domains of InlB also contribute in InlB mediated 
entry of Listeria. The IR region of InlB resembles the immunoglobin-like domain and 
participates in its interaction with the Met receptor [123, 124].  
The B repeat is not well defined. The X-ray crystallography suggest that it does 
not interact with Met the receptor, but forms structures similar to the mucin binding 
protein or the ubiquitin-like proteins. The functional significance of such a structural 
conformation is yet to be determined [125]. Previous reports using truncated mutants of 
InlB suggests that the B domain, although not required, potentiates the effects of InlB to 
activate Met [126]. The reasons for such observations are yet to be determined. 
The C terminal end of InlB harbors three GW domains [110]. Each GW domain 
consists of approximately 80 amino acids each starting with amino acids GW. InlB 
inserts into the bacterial cell surface via this GW domain [110]. This is a unique 
mechanism for protein-cell surface interaction in which the protein is partially buried in 
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the cell wall and uses lipotechoic acid as a ligand to interact with the cytoplasm [127]. 
However, such interactions are non-covalent and weak allowing dissociation of InlB 
from the bacterial cell surface. Thus in broth cultures, half of the InlB synthesized by 
listeria is found to be attached to the bacterial surface, whereas the other half is found in 
culture supernatant [127].  
1.2.4.3 Interaction of InlB with Host Cell Surface 
1.2.4.3.1 Met RTK: A significant interaction 
The Interaction of InlB with the Met is referred for bacterial entry tyrosine kinase 
family of receptors [61]. InlB binds with the extracellular domain of Met to promote 
invasion of L. monocytogenes into various cell lines [61, 112, 117, 120, 123, 126, 128-
130]. Met is widely expressed in a variety of tissues including epithelial cells in the liver, 
kidney, gastrointestinal tract, vascular endothelial cells, the placenta and the central 
nervous system [131, 132]. It consists of a disulfide-linked heterodimer with an 
extracellular α-chain and a β-chain that has extracellular, trans-membrane and 
intracellular portions [133, 134]. The α-chain and the extracellular portion of the β-chain 
forms the ligand binding site. The intracellular portion of the β-chain has a cbl binding 
domain, the tyrosine kinase catalytic domain and a cytoplasmic tail, each harboring one 
to several tyrosine amino acids. The tyrosine at position 1003 specifically binds to cbl, 
an ubiquitin ligase, which promotes receptor degradation and recycling via endocytic 
machinery [135]. The tyrosine kinase catalytic domain has tyrosine residues at position 
1234 and 1235 which get auto phosphorylated upon ligand binding and receptor 
dimerization resulting in activation of Met receptor [133]. The cytoplasmic tail harbors 
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two tyrosine residues at 1349 and 1356 which upon phosphorylation serve as a docking 
site for multiple SH2 domain containing cell signaling proteins including Gab1, Grb2, 
PLC-γ, p85 regulatory subunits of PI 3-Kinase and Src Kinase [133] . The only 
physiological ligand known to activate Met is hepatocyte growth factor (HGF) which is 
secreted by fibroblasts and stromal cells [133]. The binding of the HGF results in 
activation of Met receptor and phosphorylation of its tyrosine residues on the 
cytoplasmic tail. The cytoplasmic tail then recruits host cell signaling proteins to initiate 
a signal transduction cascade that ultimately results in cell survival, proliferation and/or 
motility [136].  
Although InlB shares no structural similarity with HGF, it acts as an agonist for 
Met [61, 120, 121]. Recently, the x-ray structure of the InlB-Met complex was 
determined which suggests that InlB and HGF do not share the same binding sites on 
Met. While the predominant site of the HGF-Met interaction is the Sema domain, Ig-3 
and Ig-4 like domains of Met, the LRR domain of InlB primary binds to Met at its Ig-1 like 
domain and only a weak interaction between IR region of InlB with Sema domain of Met 
has been observed [122, 123, 137]. Regardless of these differences, InlB mimics 
functional activity of HGF including tubulogenesis, DNA synthesis and cell motility [61, 
123]. However, the proliferative effects requires persistent stimulation of Met signaling, 
thus modulation of cell motility is the predominant effect observed during entry of L. 
monocytogenes. 
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1.2.4.3.2 gC1qr 
Using an affinity chromatography approach, the gC1qR receptor was identified 
as one of the targets of InlB. gC1q receptors are predominantly expressed in WBC‟s, 
platelets and endothelial cells. The physiologic ligand for this receptor is C1q, a member 
of the classical complement cascade [138]. gC1qR binds to InlB at its GW module [139]. 
This interaction occurs only when InlB is in the soluble form, which is consistent with the 
finding that the GW domains are in association with the cell wall [117]. The data suggest 
that the InlB-gC1qr interaction is required for efficient entry of L. monocytogene into the 
host cell [139]. However, gC1qr receptors lack the intra cytoplasmic domain and are not 
known to directly initiate intracellular signaling events [138].  
1.2.4.3.3 Heparan Sulfate Proteoglycans (HSPG) 
Heparan sulfate proteoglycans (HSPG) are the negatively charged carbohydrate 
moieties that are abundantly found on eukaryotic cell surfaces. They function to 
maintain the interaction between cell surfaces and the components of the extracellular 
matrix [140]. Jonquires et al confirmed the direct interaction between GW modules of 
InlB with HSPG. This interaction, potentiates the binding and activation of Met by InlB 
and invasion of L. monocytogenes into host cells [119, 124, 128]. Similar to gC1qR, 
HSPG is not known to initiate intracellular signaling events.  
How then, does an interaction of GW module with HSPG or gC1qR contribute in 
InlB mediated entry? GAG is essential for HGF signaling as it protects HGF from 
extracellular proteases, causes oligomerization of HGF and concentrates HGF at the 
site of Met receptors. Incubating L. monocytogenes with heparin (a soluble GAG) 
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results in dissociation and oligomerization of InlB [141]. Moreover, gC1qR binds only to 
a soluble form of InlB [117]. gC1qR also acts as a co-receptor for Met and helps with 
clustering of Met. Taken together this suggests that the interactions of GW domain with 
host cell surface dissociates InlB from bacterial cell membrane and presents it to Met 
receptor for its potent activation [107]. 
1.2.4.4 Intracellular events following InlB/Met Interaction 
1.2.4.4.1 Activation of Pi 3-Kinase 
Binding of InlB to the Met receptor causes activation of the catalytic kinase 
domain of Met resulting in its auto phosphorylation at critical tyrosine residues [61]. 
Adaptor proteins like Gab1, Shc, Grb2, cbl and CrkII are recruited to phosphorylated 
Met [130]. These adaptor proteins further recruit Type 1A PI 3-Kinase to Met resulting in 
its activation. Type IA PI 3-kinase has been identified as a critical signaling protein 
acting downstream of the MET/InlB interaction [61, 130, 142] and was shown to 
regulate F-actin rearrangement in InlB-mediated entry of Listeria( See figure 5) [143]. 
Type IA PI -3 kinase (PI3K) is a lipid kinase that regulates a variety of functions 
in eukaryotic cells, including mitogenic signaling, inhibition of apoptosis, control of 
intracellular trafficking and regulation of integrins and F-actin [144].  It mediates its 
action by converting phosphatidylinositol 3,4-bisphosphate (PI(4,5)P2, or „PIP2‟) to 
phosphatidylinositol 3,4,5 tris -phosphate (PI(3,4,5)P3 or „PIP3‟). PIP3 acts as a second 
messenger that binds directly to several proteins, including various forms of the 
serine/threonine kinases PDK1 and Akt,  and various regulators of small GTPases (Rac 
GEFs  and ArfGAPs)  [145]. By controlling PDK1, PI3K indirectly regulates the activity of 
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several protein kinases including protein kinase C (PKC) and its isoforms [146]. PI 3-
kinase can also regulate many cell processes by direct interaction with other proteins to 
modulate their activity and/or compartmentalization [147-149]. Proteins that act 
downstream of PI 3-kinase that cause cytoskeleton changes and favor uptake of L. 
monocytogenes into the host cell are not yet known. 
The Ras-Map kinase pathway is also activated following InlB /Met association. In 
fact, InlB is a more potent activator Ras-Map Kinase pathway than HGF. These 
differences are hypothesized to be due to different binding sites of HGF and InlB on 
Met.   
1.2.4.4.2 Subversion of Host Actin Nucleation Machinery 
Cytoskeleton rearrangements play a critical role in the entry of Listeria. Previous 
studies demonstrated that treatment of host cells with inhibitors of actin polymerization, 
such as cytochalasin D, resulted in a marked decrease in the entry of L. 
monocytogenes [77]. The role of the Arp2/3 complex, which generates branched actin 
filaments required for the formation of phagocytic cups, in entry of L. monocytogenes is 
well established. The activation of the Arp2/3 complex is mediated primarily via 
Rac/Wave and cdc42/ N-Wasp pathways [124, 150]. The contribution of Ena/Vasp and 
Abi proteins to preserve the newly formed actin filaments has also been demonstrated 
[151, 152]. The efficient uptake of L. monocytogenes also requires de-polymerization of 
the actin filaments. Such activities are mediated via the Cofilin/Lim kinase pathway 
[153]. AlThough, how these pathways are linked to Met activation following InlB 
stimulation is not yet known. Interestingly, the activation of PI 3-Kinase is found to be 
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essential for Rac1 activity following InlB stimulation [154]. PI 3-kinase can potentially 
regulate the activity of several guanine nucleotide exchange factors (GEF) needed for 
Rac1 and cdc2 activation. The GEFs which act downstream of PI 3-kinase to cause 
activation of Rac1 and cdc42 are not yet identified. 
1.2.4.4.3 Subversion of the Clathrin Dependent Endocytic Machinery 
Endocytosis is a process by which the cell mediates uptake of solutes, fluids and 
certain small molecules [155]. Endocytosis also plays a critical role in cell signaling as it 
allows recycling and degradation of several receptors, thus acting as a check point to 
prevent persistent cell stimulation. Consistently activated Met receptor also undergoes 
endocytosis mediated degradation following stimulation by HGF and purified InlB [156, 
157]. Endocytic vesicles are typically small and allow internalization of only very small 
molecules [155]. Interestingly, some components of endocytic machinery, including 
clathrin, adaptor proteins Eps 15 and Grb2, ubiquitin ligase cbl and lipid rafts, have 
been shown to play essential roles in the entry of L. monocytogenes. Depletion of these 
molecules via RNA-interference abrogates Listeria entry [158, 159]. The mechanism by 
which these proteins help in the entry process is not yet known. One possibility is that 
clathrin forms large lattices to mechanically help the internalization process. Another 
possibility is that these molecules influence signal transduction events to regulate F-
actin changes needed for Listeria entry. To support this notion, the role of lipid rafts in PI 
3-Kinase dependent activation of Rac1 following InlB stimulation has been 
demonstrated [154]. The ability of clathrin to serve as a scaffolding protein in controlling 
the activity and/or membrane localization of many adaptor proteins and lipid kinases is 
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also known [160]. Cbl, an ubiquitin ligase, can directly bind and activate Pi 3-Kinase 
[161]. In turn, the activation of PI 3-Kinase can help the maturation of newly forming 
endosomes by recruiting essential molecules like Rab and SNX family of proteins [147]. 
However the association between the endocytic pathway and Pi 3-Kinase signaling in 
entry of Listeria is yet to be determined. 
1.2.5 Hypothesis 
PI-3 kinase mediated signaling events are critical for invasion of L. monocytogenes.  
PI-3 kinase can regulate the activity of many host cells proteins to cause cytoskeleton 
rearrangements. In order to understand the molecular mechanisms involved in invasion 
of L. monocytogenes, it is first essential to identify the host proteins that play a critical 
role in this process. 
1.3 Chlamydia trachomatis 
1.3.1 Background and Taxonomy 
The order Chlamydiales includes organisms that possess unique biphasic 
developmental cycles, which alternate between an extracellular infectious form, „the 
elementary body‟ (EB), and an intracellular replicative form, „the reticulate body‟ (RB) 
[162]. The species in this order are broadly subcategorized into being environmental 
and pathogenic organisms. The ubiquitously found environmental organisms include the 
species in the families Parachlamydiaceae, Waddliacea and Simkaniacae. These 
organisms predominantly infect unicellular eukaryotes like amoebae [163, 164]. The 
pathogenic group includes species of the genera Chlamydia and Chlamydophila that 
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tend to infect complex eukaryotic organisms [163]. The genus Chlamydia includes three 
species, namely C.trachomatis, C. muridarum and C. suis, whereas the genus 
Chlamydophila include six species viz., C. pneumonia, C. abortus, C. caviae, C. 
pecorum, C. psittaci and C. felis [163]. In 2009, the Chlamydia basic research society 
meeting was held in Little rock, Arkansas, where the decision was made to merge the 
genus Chlamydia and Chlamydophilia into one family of Chlamydia (see figure 6). 
Within each species are many different serovars, which cause different diseases, elicit 
variable host immune responses, and show variations in their morphology. Serovars are 
distinguished based on variable host antibody response to the „major outer membrane 
protein‟ (MOMP), the main surface antigen in pathogenic chlamydial species. 
 
1.3.2 Epidemiology, Infection and Pathogenesis 
Chlamydia can infect a wide variety of hosts including mice, hamsters, cattle, 
sheep, pigs, koalas, ferrets, pigeons, budgerigars, parakeets, horses and humans [165]. 
However, not all chlamydial species infect humans. Infections in humans are usually 
caused by C. trachomatis, C. pneumoniae, and C. psittaci. C.trachomatis serovars A, B, 
Ba and C are responsible for causing ocular disease „trachoma,‟ whereas C.trachomatis 
serovars D-K cause urogenital infections resulting in cervicitis, urethritis, endometritis, 
salpingo-oophoritis, infertility and ectopic pregnancy. C.trachomatis serovars L1, L2 and 
L3 cause a more invasive disease called lymphogranuloma venereum, which mainly 
affects the lymph nodes.  C. pneumoniae and C. psittaci usually infect the respiratory 
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tract resulting in a mild upper respiratory infection, but they can sometimes cause life 
threatening pneumonia [166].  
Chlamydia trachomatis serovar A-C are responsible for causing trachoma, which 
is a leading cause of preventable blindness in developing and underdeveloped 
countries [167]. It accounts for 16% of the blinding population globally [168]. Poor 
hygiene, the unavailability of clean water and lack of health care resources are the main 
factors responsible for the high incidence and prevalence of trachoma [169]. The 
infection usually occurs in children within the age group of 0-4 years. Without treatment, 
the chronic irritation causes conjunctival and corneal scarring that leads to 
blindness[169]. „SAFE,‟ a strategy whose components include Surgery, Antibiotics, 
Facial cleanliness and Environmental improvement, is currently a major project funded 
by the WHO with an aim to eradicate trachoma by 2020[170].  
Chlamydia trachomatis serovar D-F is the most common sexually transmitted 
disease in the United States [171, 172]. Each year it is responsible for over 1 million 
new cases in the U.S. and 92 million new infections globally. It is estimated that one out 
of every seventy-three individuals are infected by Chlamydia [173]. In 2007, a survey 
done by the Center for Disease Control and prevention (CDC) reported an infection rate 
of 13.2 % in females and 7.2 % in males between 16 and 24 years of age. The main risk 
factor for acquiring C. trachomatis infection is sexual promiscuity. It can be transmitted 
via vaginal, anal, or oral sexual contact. The majority of infections are asymptomatic 
and go unrecognized. Acute clinical symptoms include urethritis, proctitis and 
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epididymitis in males and cervicitis, urethritis and salpingitis in females. Subclinical or 
chronic infections lead to complications like pelvic inflammatory diseases, ectopic 
pregnancy and infertility[174]. Infection can also be transmitted from infected mother to 
newborn resulting in conjunctivitis and/or pneumonia [175]. 
Unlike C. trachomatis serovars A-K, which cause superficial mucosal infections, 
serovars L1- L3 infect deeper tissues, especially submucosa and the lymph nodes 
[176]. These serovars are responsible for the infectious disease known as 
Lymphogranuloma venereum (LGV). LGV is also a sexually transmitted disease which 
usually occurs in homosexuals and HIV positive patients. Clinical manifestation includes 
papular lesions followed by anal strictures and lymphedema [176]. Because of the 
rapidly changing sexual practices in general populations a number of recent outbreaks 
of LGV have been reported in Europe and the United States [177].  
C. pneumoniae usually infects respiratory epithelium and causes acute 
respiratory tract infections including pneumonia, bronchitis, otitis media, pharyngitis and 
sinusitis [178, 179]. Human exposure to C. pneumoniae is very common and it is 
estimated that 80% of the world‟s population have been exposed to C. pneumonia at 
any given point [180]. However, acute infection usually occurs in children under 5 years 
of age [181, 182]. It is usually transmitted from person to person via respiratory droplets 
[182]. Recently, the role of C. pneumonia in chronic inflammatory conditions like 
atherosclerosis and destructive joint diseases has also been suggested [183]. 
27 
 
C. psittaci is a zoonotic disease which usually occurs in birds like parrots, 
parakeets and canaries [184]. Humans are rare incidental hosts. It tends to occur in 
individuals having occupational exposure to birds like poultry farm workers and 
veterinarians [185-187]. The disease caused by C. psittaci is known as psittacosis, also 
referred to as parrot fever. It results in acute respiratory infection causing severe 
bronchitis and pneumonia [185]. Other symptoms include high fever, joint pain, 
conjunctivitis and epistaxis. In severe cases it carries a mortality risk of ~1%. 
The majority of acute infections caused by chlamydia are cleared by host innate 
and adaptive immune responses without any major consequences. However, in 
susceptible individuals repeated or persistent infection can lead to chronic inflammation 
with subsequent scarring, fibrosis and anatomical defects [188].  
Upon transmission into the humans, the first line of defense against Chlamydia is the 
innate immune response. Since chlamydia infects ocular, respiratory, or genital 
epithelium, the first line of defense is the mucosal barrier [189]. The mucosa not only 
serves as a physical barrier but also contains several antimicrobial proteins including 
lysozymes, defensins and complement proteins, which resist the establishment of a 
chlamydial infection [189, 190].  
Epithelial cells respond to chlamydial infection by producing pro-inflammatory 
cytokines like IL-8, IL-6, GM-CSF and GRO-α [191]. These cytokines recruit and 
activate polymorphonuclear neutrophils, macrophages, peripheral blood monocytes, 
dendritic cells and natural killer cells [174]. These cells further potentiate the 
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inflammatory response by releasing IFN-γ and matrix metalloproteinase [174]. The high 
levels of IFN-γ activate Indoleamine 2,3 dioxygenase (IDO), which stops the production 
of tryptophan, an essential amino acid required for replication of EBs [174, 192]. IFN-γ 
also induces nitric oxide synthase in macrophages and epithelial cells leading to 
activation of nitric oxide based killing mechanisms [193, 194].  
Adaptive immunity in the form of T and B cells also contribute to fight chlamydial 
infections. Antigen presenting cells such as macrophages and dendritic cells engulf 
chlamydia and infected epithelial cells and process chlamydial antigens via the MHC 
class II mediated pathway [195]. These antigens are recognized by CD4+ T-cells. CD4-
TH1 cells are believed to play a significant role in clearing chlamydial infections by 
producing large amounts of inflammatory cytokines [192]. Infected epithelial cells also 
cause recruitment of CD8+ cytotoxic T-cells via MHC class I antigen presentation [174]. 
The role of B-cells in chlamydial infection is controversial [196, 197]. There are many 
reports confirming the production of chlamydia specific neutralizing antibodies by B-
cells, which promotes opsonization and phagocytosis of EBs [196, 198, 199]. However, 
mice deficient in B-cells have been shown to fight chlamydial infections as efficiently as 
their normal counterparts [197]. Thus, it is believed that T-cell mediated responses are 
predominantly involved in chlamydial infection. However, such adaptive immunity is 
short lived and does not confer full protection to subsequent infections [200-202]. This is 
due to both rapid reduction in antibody titers as well as reduction in antigen specific T-
cells [203, 204]. Interestingly, repeated exposures to chlamydia elicit more severe 
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inflammatory damage probably due to hyper immunization or delayed type 
hypersensitivity [198, 205, 206].  
One mechanism by which chlamydia can respond to acute inflammatory host 
immune responses is by entering into a persistent state characterized by aberrant RBs. 
The persistent state is defined as the ability of the chlamydia to remain in a dormant and 
non-replicative form within the host for an extended period of time [207]. In tissue 
culture, EBs enter into the persistent state in response to penicillin treatment, IFN-γ, 
continuous infections or nutritional deficiency [208]. Aberrant RBs are characterized as 
enlarged forms of RBs, which produce less surface antigen such as MOMP, Outer 
membrane protein B (OmpB) and lipopolysaccharide (LPS) [207]. The DNA replication 
machinery is active in aberrant RBs and they continue to accumulate DNA. However, 
they are arrested in the growth cycle and do not divide or transform to EBs [209-211]. In 
the absence of adverse conditions, these aberrant RBs transition back and continue to 
propagate. The exact molecular details of such reversible transitions are not yet known. 
Such waxing and waning of the chlamydial developmental cycle is believed to be 
responsible for continuous residual infection causing chronic inflammatory damage to 
the host. There is ample clinical evidence to support this hypothesis. For example, 
chlamydial proteins, in absence of recoverable organism, can be detected at the site of 
infection long after the resolution of an acute episode of infection [212-214]. Children 
living in endemic areas have developed trachoma decades after moving to non-endemic 
zones probably due to the reactivation of an initial asymptomatic infection [215]. 
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Persistent infection by C. pneumoniae is also believed to be a plausible etiology in 
development of asthma and atherosclerosis [216, 217].  
Autoimmune inflammatory response to chlamydial antigens has been implicated 
in the pathogenesis of diseases caused by chlamydia.  High expression of immunogenic 
Heat shock protein 60 (Hsp60) by aberrant RBs elicits strong antibody responses 
resulting in production of anti-Hsp antibodies by the host. Hsp from different organisms 
share great sequence and structural homology [218]. These antibodies can cross react 
with host Hsp to initiate autoantibody mediated destruction of host tissues [198]. Hsp 
proteins can also directly activate toll like receptors 2 (TLR2) and trigger production of 
inflammatory cytokines transforming growth factor-β (TGF-β) and fibroblastic growth 
factor (FGF) by many cell types including macrophages, T and B lymphocytes [219]. 
Together this can result in fibrosis and scarring causing anatomic defects [198]. 
Host susceptibility is also implicated in development of pathology following 
infection by Chlamydia. HLA-A31 and A6802 alleles have been strongly associated with 
development of pelvic inflammatory disease (PID) and trachoma respectively [220, 221]. 
Polymorphism in the promoter regions of inflammatory cytokines including TNF-α have 
also been associated with increased incidence of scarring following chlamydial infection 
[222]. 
1.3.3 Developmental Cycle of C. trachomatis 
Species of Chlamydia utilize a unique developmental cycle in which bacteria 
transition from the infectious spore-like elementary body (EB) to the metabolically active 
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reticulate body (RB) within the protective confines of a membrane bound 
parasitophorous vacuole termed the inclusion [223]. The invasive EB is formed in the 
mid to late stages of the intracellular development cycle as the RBs differentiate back to 
EBs and are packed with metabolites and proteins designed to facilitate extracellular 
survival and reinfections. [224, 225]Additional infectious cycles arise from EBs that are 
released and disseminate from infected tissues (see figure 7) [226]. 
1.3.3.1 Attachment and Invasion 
Being an obligate intracellular organism, invasion into eukaryotic host cells is the 
most critical step in the biology of chlamydia. The EB attaches to the mucosal epithelial 
cell membrane through a reversible electrostatic interaction [227]. Heparan sulfate 
proteoglycan (HSPG/GAG) mediates the initial reversible binding of EBs to the host cell 
surface, as preincubation of bacteria or host cell with heparan sulfate causes diminished 
entry of EBs [228-232]. Furthermore, treatment of C. trachomatis and C. pneumoniae 
EBs with monoclonal antibodies targeting heparan sulfate also reduces invasive 
capacity of EBs [233]. Similarly, chemically modified heparan sulfate or heparinase 
treatment of EBs or host cells prevented infection by C. trachomatis serovar E and L2 
[231, 232]. Although the role of chlamydial GAG in attachment has been suggested in 
many studies, no chlamydial genes that can synthesize a structural analogue of GAG 
have yet been identified. It has also been proposed that chlamydia acquires GAG from 
the host golgi apparatus, which is a site of proteoglycan synthesis [234, 235]. 
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The initial attachment is followed by temperature dependent irreversible binding 
of putative adhesins like MOMP, LPS, and Pmps to host cell surface receptors [236]. 
Many host cell surface receptors have been identified that favors irreversible interaction 
between chlamydia and host cell surface. This includes platelet derived growth factor 
receptor (PDGFR), fibroblastic growth factor receptor (FGFR), cystic fibrosis 
transmembrane conductance regulator (CFTR) [237-239]. Such interactions activate 
host signal transduction pathways and also favor contact dependent activation of the 
type III secretion machinery (T3SS) present on the surface of the EBs [240]. T3SS is a 
needle like apparatus that gram negative organisms use to deliver effector proteins into 
eukaryotic host cells[241] . Using the T3SS apparatus, EBs deliver several effector 
proteins into the host cells including CT456 (Tarp), CT166 and CT694 [242-244]. These 
events together cause dramatic rearrangement of the actin cytoskeleton favoring uptake 
of EBs into a membrane bound vacuole. Such effector mediated entry of 
microorganisms is known as a „trigger mechanism.‟ 
1.3.3.2 Transition from EBs To RBs 
Immediately upon entry into the endocytic vesicle, EBs begin to differentiate into 
RBs. Such transition occurs within the first two hours post invasion and involves at least 
two defined mechanisms. The condensed nucleoid DNA of EBs begin to disperse to 
form free chromatin, which results in increased transcriptional activity. The 
transcriptional activity can be observed as early as 15 minutes following invasion [245]. 
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Secondly, the infectious particles are rendered non-infectious and become metabolically 
active.  
1.3.3.3 Intracellular Survival and Replication 
Throughout its intracellular development, chlamydia remains confined within 
membrane bound vesicles called “the inclusion”. The naïve inclusion is initially resistant 
to degradation by endo-lysosomal fusion. Although the exact molecular details of non-
fusogenic properties of early inclusions are elusive, the surface proteins of EBs are 
thought to be involved in this process.  Another characteristic feature of early inclusion 
is the migration towards the peri-nuclear region that is close to the golgi apparatus. 
Inclusion migration requires dynein and other unknown phosphoproteins that drive 
migration toward the host microtubule organizing center (MTOC) [246, 247]. The 
transcriptionally active RBs decorate the inclusion membrane by expressing several 
inclusion membrane proteins. Such matured inclusions are not recognized by the host 
cells as a an endosome, but rather as an exocytic vesicle, thereby avoiding destruction 
via fusion with lysosomes. 
Several genes for structurally and functionally distinct inclusion membrane 
proteins (Inc) have been identified in the chlamydial genome. Many of these Inc‟s (IncD-
IncG) are expressed by RBs during the early phase of the chlamydial developmental 
cycle [248, 249]. RBs use type III secretion apparatuses to secrete these Inc proteins 
within the inclusion. All Inc‟s share a conserved hydrophobic domain of 40-60 amino 
acids, which allow these proteins to be inserted into the inclusion membrane [250]. 
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While the functions of many Inc proteins are elusive, some of these Inc proteins are 
thought to mediate interaction of inclusion with host vesicles either directly or by 
recruiting host proteins involved in vesicular trafficking. IncA harbors a eukaryotic 
SNARE like domain that allows homotypic fusion of inclusions [227, 251]. Therefore, 
even if multiple EBs invade a cell, only one inclusion body per cell is eventually formed 
[249].  However, in the case of C. pneumoniae, the EBs do not coalesce and form 
multiple small inclusions. IncA can also directly mediate fusion of the inclusion with host 
vesicles. Some Inc proteins cause recruitment of Rab GTPases to the inclusion 
membrane resulting in its interaction with host vesicles. For example, C. trachomatis Inc 
CT229 has been shown to recruit Rab4, and C. pneumoniae Inc Cpn0585 recruits 
Rab1, Rab10 and Rab11 [252, 253]. Such interactions allow chlamydia to evade 
intracellular immune responses and also help in acquiring essential nutrients like 
sphingolipids, sterols and glycerophospholipids required for inclusion expansion [254-
256].  
Prevention of host cell cycle progression, apoptosis and inflammatory responses 
is critical for intracellular survival of developing inclusions. Chlamydia has developed 
several strategies to influence these host responses. Chlamydial infection into host cells 
causes cleavage and degradation of cyclin B1, which subsequently leads to cell cycle 
arrest [257]. IncG sequesters host protein 14-3-3β to prevent phosphorylation of pro-
apoptotic BAD [258, 259]. NFKB signaling involved in pro-inflammatory cytokine 
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production is interrupted by effector proteins including CT441, ChlaDub1 and CP0236 
[260, 261].  
As the development of an inclusion progresses, RBs express another set of mid-
cycle genes including transporter proteins and T3SS. This allows nutrient acquisition 
needed for the replication of RBs. As the RBs divide by binary fission, the inclusion 
body increases in size to accommodate newly dividing RBs. Some RBs lose contact 
with the inclusion membrane, possibly due to retraction of the T3SS apparatus, and 
revert back to the infectious EB [249, 262, 263]. This secondary differentiation from RB 
to EB involves prepackaging infectious EBs with proteins involved in invasion and 
nuclear condensation [209, 264, 265]. 
1.3.3.4 Egress 
The intracellular developmental phase of chlamydia lasts for approximately 36 
hours [266]. The extracellular release of newly formed EBs involves at least two distinct 
mechanisms. The first mechanism involves cysteine protease induced cell lysis, causing 
disruption of both the inclusion and host plasma membrane [226]. Thus, the naked EBs 
are directly released into the extracellular spaces. The second mechanism involves a 
cell lysis independent extrusion of the membrane bound inclusion. This mechanism 
involves N-wasp mediated actin polymerization and cytoskeleton rearrangements that 
ultimately push the entire inclusion out of the cell [226]. Once the contents of inclusion 
are released in the extracellular environment, the non-infectious RBs die, whereas the 
infectious EBs are ready to infect new host cells to repeat the cycle. 
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1.3.4 Invasion into Mammalian Cells: The Trigger Mechanism 
1.3.4.1 Attachment 
Following the initial reversible interaction between EBs and the epithelial cells, an 
irreversible binding step that is temperature dependent has been characterized[236]. 
The molecular details of such irreversible interactions are not yet understood. It is 
hypothesized that the irreversible interaction results from the insertion of a type III 
secretion apparatus or an as yet uncharacterized receptor-ligand interaction. Many 
putative surface adhesins and host receptors have been identified and will be discussed 
below. However, no single adhesin-receptor interaction is yet characterized, which is 
found to be essential for attachment or entry of all chlamydial species. It is believed that 
chlamydia uses multiple modes to interact with host cell surfaces for its efficient uptake. 
Genetic intractability of chlamydia, species specific differences in surface adhesins and 
the uses of several host cell lines has complicated the issues in characterizing the 
general mechanism used by chlamydial species to interact with the host cell surface.  
Major outer membrane protein (MOMP) 
MOMP is the most abundant protein found on the surface of both EBs and RBs 
[267]. It accounts for 50-60% of total outer membrane protein mass in EBs and almost 
100% in RBs [267]. MOMP is conserved among all pathogenic chlamydial species. It 
consists of five constant domains that are identical among different chlamydial species, 
interspersed with four surface exposed variable domains [268]. The variable domains 
are linked to glucosamine containing sulfated polysaccharides [269]. Serovars of 
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chlamydia are distinguished based on the host antibody response to the variable 
domains of MOMP. Several observations suggest the role of MOMP in the attachment 
of EBs to the host cell surface. Treatment of host cells with MOMP antibodies can inhibit 
attachment and entry of C. trachomatis EBs[270]. The polysaccharide moiety of MOMP 
also seems to be important in host cell surface binding as N-glycanase treatment 
abrogates entry [269-271]. However, serovar specific differences were observed in the 
role MOMP as adhesin as trypsinization induced cleavage of variable domains of 
MOMP prevented attachment of C. trachomatis serovar B, but not of L2 [272, 273]. 
Outer membrane complex protein B (OmcB) 
OmcB is a cysteine rich 60 kDa protein present on the surface of EBs. It has 
been thought to provide osmotic stability and structural rigidity to EBs. It is also 
predicted to function as adhesin and is thought to prevent fusion of the early inclusion 
with lysozomes [274, 275]. Heterologous expression of C. pneumoniae OmcB in yeasts 
resulted in binding of yeasts to epithelial cells [276]. OmcB possesses a 20 amino acid 
domain that binds to heparin [277]. Addition of heparin prevented binding of 
recombinant purified LGV OmcB to epithelial cells. Also, attachment of LGV EBs was 
abrogated in presence of excess recombinant OmcB protein. But, OmcB was not found 
to be important for attachment of C. trachomatis serovar E [278].  
Polymorphic membrane protein (Pmp’s) 
Pmp‟s are a family of surface proteins that includes 9, 17 and 20 members in C. 
trachomatis, C.psittaci and C. pneumoniae respectively [279-281]. The pmp genes are 
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clustered in the chlamydial genome and show a great degree of variability in their 
structure [282]. The presence of several conserved pmp genes among different 
chlamydial species suggests its important role in chlamydial biology. Heterologous 
expression in yeast of many members of the Pmp family resulted in the attachment of 
yeast with epithelial cells suggesting the possible role of these Pmps as adhesin [283].  
Crane et al recently demonstrated that antibodies targeting PmpD neutralizes 
chlamydial infection in vitro. Moreover, antibody targeting other surface membrane 
proteins like MOMP can block the neutralizing effects of anti-PmpD antibody, 
suggesting role of Pmp in decoy like immune evasion [284]. Recent evidences also 
suggest the role of some Pmps as auto transporters that help in early transition of EBs 
to RBs [285].  
Lipopolysaccharide (LPS) and Heat shock protein 70 (Hsp70) 
LPS is present in the cell wall of all gram negative bacteria. The chlamydial LPS 
differs from the other gram negative LPS in that it does not elicit strong endotoxic 
response in the host [286, 287]. Immunoprecipitation studies identified Cystic Fibrosis 
Transmembrane Receptor (CFTR) receptor as a probable interacting partner of LPS 
[239]. Hsp70 is another surface exposed protein present on the surface of EBs. Hsp70 
is believed to mediate attachment of EBs with endometrial cells as heterologous 
expression of Hsp70 in E. coli favored attachment to endometrial cells [288]. 
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The host receptors 
Several putative host cell surface receptors have been proposed to favor 
attachment of EBs in a species/serovar specific manner. Platelet derived growth factor 
receptors (PGFR-β) have been shown to play a critical role in attachment of C. 
trachomatis serovar L2 to Hela and S2 cell lines [237]. Later studies implicated the role 
of PGFR-β in attachment of C. pneumoniae [289]. In vivo experiments using cystic 
fibrosis transmembrane receptor (CFTR) knockout mice suggest the role of CFTR in EB 
uptake. Chlamydial LPS has been shown to co-precipitate with CFTR receptors.  
Treatment of Hela cells with mAb targeting CFTR resulted in diminished entry of C. 
trachomatis EBs [239]. C. pneumoniae MOMP has been suggested to interact with 
Insulin-like growth factor receptors-2 (IGFR-2) as treatment with Mannose-6-phosphate 
abrogates attachment of EBs [290]. Protein disulfide isomerase (PDI) knock out 
Chinese hamster ovarian (CHO) cell lines show diminished attachment of C. 
trachomatis EBs, which can be reversed by ectopic expression of PDI suggesting the 
possible role of PDI in chlamydial entry. Recently, the requirement of PDI in the 
attachment of other chlamydial species has also been confirmed. The enzymatic activity 
of PDI is not necessary for EB attachment and it is believed that PDI acts as a co-
receptor to favor attachment of EB‟s to yet unidentified host cell surface receptors [291]. 
1.3.4.2 Entry  
Chlamydia is capable of inducing its own uptake so efficiently that the process is 
termed as „parasite specific phagocytosis.‟ This process requires the formation of an 
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actin pedestal and hypertrophic microvilli on the host cell surface [292]. Attachment of 
EBs to the host cell surface causes recruitment of actin and treatment of host cells with 
cytochalasin D, an inhibitor of actin polymerization, abrogates chlamydia entry [292-
295]. Actin polymerization during chlamydial entry involves active participation of both 
the host cytoskeleton machinery and chlamydial effector protein Tarp, which will be 
discussed below. 
1.3.4.2.1 Host Factors 
The Arp2/3 complex is recruited at the site of chlamydial attachment and 
disruption of its activity abrogates chlamydial entry, suggesting the important role of the 
Arp2/3 complex in chlamydial invasion [226, 296, 297]. Chlamydial species differentially 
regulate the activation of Arp2/3 complex. C. trachomatis requires Rac, whereas C. 
caviae requires both Rac and cdc42 for efficient uptake into host cells [298, 299]. 
Activation of Rac causes Abi and Wave2 dependent activation of the Arp2/3 complex 
[296]. Ezrin, a member of the ezrin-radixin-moesin (ERM) family, which links the actin 
cytoskeleton to the plasma membrane, has also been identified as a critical player in C. 
trachomatis entry [300]. Ezrin gets phosphorylated by yet unidentified kinases following 
EB-host interaction[300].  Phosphorylated ezrin then associates with actin near the tips 
of microvilli. Furthermore RNA interference of ezrin inhibited chlamydia entry [301]. 
Signaling events that occur downstream of EB-host interactions to activate host 
cytoskeleton machinery are not completely understood. Previously, PDGF-β receptor 
dependent activation of cortactin, Wave2, and Vav2 has been suggested to have a role 
in C. trachomatis entry. However, blocking of PDGF receptors only partially inhibited 
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entry [237]. FGFR receptor is recently identified to favor attachment of EBs [238]. 
However, its role in activation of the Arp2/3 complex to cause chlamydial entry is not yet 
determined. It is hypothesized that multiple pathways converge at multiple levels to 
activate the Arp2/3 complex and induce the efficient uptake of EBs. Some pathogenic 
microorganisms have been shown to harbor proteins that can directly activate Arp2/3 
complex [6]. However, no such chlamydial effectors have been definitively identified 
with these capabilities.  
1.3.4.2.2 Chlamydial Effector Proteins and The Tarp 
One of the well characterized modes of chlamydial entry is via translocation of its 
effector proteins. At least three effector proteins have been identified so far that are 
believed to play an essential role in chlamydial entry including CT456 (Tarp), CT166 
and CT684 [64, 242, 244]. These effectors exhibit different functional capabilities to 
regulate cytoskeleton rearrangement [64, 242, 244]. The Tarp has been demonstrated 
to increase the rate of actin polymerization in vitor [64]. CT166 has been shown to 
inhibit the activity of host Rac GTPases [244]. CT694 associates with host protein 
Desmoyokin (AHNAK) to modulate the stress fibers which could also be important in 
invasion [242].  
The Tarp  
Identification: Several phosphorylated proteins of varying molecular weights 
accumulate within the host cytoplasm in response to C. trachomatis infection [302, 303]. 
Initially these proteins were thought to be of host origin. Later, mass spectrometric 
analysis revealed one such protein to be of bacterial origin [243]. Because this protein 
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was found to be associated with the recruitment of actin, it was named translocated 
actin recruiting protein, “Tarp”. Tarp was observed to be translocated into the host cells 
using a heterologous expression system in Y. pseudotuberculosis [243]. Genomic 
analysis later revealed the presence of Tarp gene in all pathogenic species of 
chlamydia [243, 280, 304, 305]. However, Tarp orthologs from different chlamydial 
species differ in their sizes and share lower levels of sequence homology relative to 
other chlamydial Tarp genes [306]. At the amino acid level, the Tarp from C. 
trachomatis serovar D, C. muridarum, C. caviae and C. pneumoniae share 94.3, 59, 43 
and 46 percent sequence homology to C. trachomatis L2 Tarp, respectively [306]. In 
spite of these differences some important functional domains are found to be conserved 
among different Tarp orthologs identified so far (see figure 8) [307]. 
Structure: C. trachomatis serovar L2 Tarp (CT456/Tarp) consists of a single 
polypeptide of 1005 amino acids with a molecular weight of ~105kDa. The N-terminal 
200 amino acids of Tarp possess a signal sequence that is recognized by chlamydial 
chaperone protein Slc-1(CT043), which shuttles the Tarp protein into a Type III 
secretion apparatus for effective delivery [308]. Tarp harbors three known functional 
domains including the N-terminal phosphorylation domain (PhosD), the C-terminal 
proline rich oligomerization domain (PRD) and the Wiskott-Aldrich syndrome protein 
(WASP)- homology-2 (WH2) like actin binding domain (ABD) [64, 243, 306]. While the 
phosphorylation domain is present only in Tarp that belongs to serovars in the C. 
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trachomatis group, the proline rich domain and actin binding domain are conserved 
among all Tarp orthologs (see figure 8) [306, 307].  
The phosphorylation domain (PhosD) consists of tandem repeats of ~50 amino 
acids that are rich in tyrosine [306]. The PhosD in LGV strains of C. trachomatis harbor 
6 Tyrosine rich repeats, whereas trachoma strains harbor only 3 such repeats (See 
figure 8). Four to five tyrosine amino acid residues are found within each repeat. The 
2nd and 3rd tyrosine residues within the 1st repeat and probably the corresponding 
tyrosine residues in each subsequent repeat are the target of host cell kinases [309]. A 
variety of host cells tyrosine kinases are identified to phosphorylate Tarp including Src, 
Fyn, Abl, Syk and Yes [309, 310]. 
The proline rich domain (PRD) consists of a polypeptide of ~25 amino acids that 
are rich in proline amino acids. The presence of several proline amino acid residues 
imparts hydrophobicity to Tarp. In eukaryotic cell lines, ectopically expressed Tarp tends 
to form aggregates in intra-cytoplasmic aqueous environment [243]. The ability of Tarp 
to form aggregates is essential for actin nucleation activity of certain Tarp orthologs that 
harbor only one ABD [307].  
The actin binding domain (ABD) consists of a polypeptide of 10-12 amino acids 
that forms an α-helical structure like many other known actin binding domains [311]. 
Tarp can directly bind to monomeric (G-actin) and filamentous (F-actin) forms of actin 
via its ABD [64]. The number of actin binding domains varies among different Tarp 
orthologs. C. trachomatis serovar LGV and C. pneumoniae Tarp harbor one ABD, C. 
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trachomatis serovar D and C. caviae harbor three ABDs, whereas C. trachomatis 
serovar A and C. muridarum harbor four ABDs [307] (See figure 8). 
Functions of Tarp in entry of Chlamydia: EBs are packaged with pre-
synthesized Tarp. Tarp is not found to be surface exposed as antibodies targeting Tarp 
do not recognize EBs [243]. Interactions of EB with the host cell surface results in 
contact dependent activation of the T3SS apparatus and translocation of Tarp into the 
host cell cytoplasm [243]. Within minutes following its translocation into the host cell 
cytoplasm, C. trachomatis Tarp is tyrosine phosphorylated at its phosphorylation 
domain, although the significance of Tarp phosphorylation is not yet known. Tarp is 
hypothesized to participate in the observed cytoskeletal rearrangements required for 
chlamydia entry and remains associated to the inclusion membrane following invasion 
[243].  
The first evidence suggesting a role for Tarp in entry of Chlamydia was the 
observation that ectopically expressed GFP-Tarp fusion co-localized with actin [243]. 
Jewett et al later demonstrated the functional ability of Tarp to bind and nucleate actin 
using an in vitro actin binding and polymerization assay [64]. The actin nucleating ability 
of Tarp is attributed to the presence of ABD and PRD domains. Tarp, via its actin 
binding domain, binds monomeric G-actin, while the PRD domain helps different Tarp 
molecules to form aggregates. Together this results in interaction of three monomers of 
actin, which is the rate limiting step to generate filamentous actin (F-actin).  Some Tarp 
orthologs harbor 3 or 4 actin binding domains and can nucleate actin independent of 
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their ability to form aggregates. Jewett et al demonstrated in vivo functional significance 
of Tarp ABD by microinjecting the Hela cells with antibodies specifically targeting ABD 
which abrogated chlamydial entry [307].   
An indirect role for Tarp in modulating host cytoskeleton machinery has also 
been suggested [296, 312]. There is evidence linking the phosphorylation domain of 
Tarp to the activation of Arp2/3 complex [312]. Biochemical assays using fusion of a 
single tyrosine rich repeats of Tarp with the N-terminal domain of CD4 receptors 
suggests phosphotyrosine dependent recruitment of Sos1/Abi/Eps8 or Vav2/PIP3 [296]. 
Formation of such a complex is believed to cause Rac dependent activation of Arp2/3 
complex [299]. Interestingly, inhibition of Tarp phosphorylation using general kinase 
inhibitors does not prevent chlamydial entry, although it does prevent inclusion 
development [309]. In light of these controversial evidences, two models for entry of 
chlamydia have been proposed. One model proposes an independent role of Tarp in 
chlamydial entry, whereas the other model also links the phosphorylation domain of 
Tarp to Arp2/3 activation (see figure 9). 
Tarp may harbor additional domains: Unlike other bacterial pathogens, up 
until recently chlamydial species were intractable to genetic manipulation. Most of our 
knowledge about the functions of chlamydial virulence factors come from scientific 
approaches that employed in vitro analysis. Large proteins like Tarp posed additional 
challenges as it was impossible to obtain recombinant full length proteins of optimum 
quality required for biochemical in vitro assays. Despite these challenges, several 
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scientific groups were successful in characterizing at least some functions of Tarp by 
employing its truncated mutants. However, such studies were very focused and directed 
towards one particular aspect of Tarp‟s function in chlamydial biology. In depth 
understanding of Tarp requires revisiting the known functions of individual domains in 
full length Tarp using in vitro and possibly in vivo studies. 
Tarp possesses certain characteristic features that tempt one to speculate 
additional functions of Tarp in chlamydia entry. The actin binding domain of Tarp has 
been shown to bind both G-actin and F-actin. While the ability to bind G-actin is 
essential for Tarp‟s nucleating activity, the significance of Tarp‟s interaction with F-actin 
is yet unknown. Many proteins that bind and/or nucleate G-actin also have capacity to 
bundle, severe, cap or branch F-actin [311, 313, 314]. For example, eukaryotic Arp2/3 
complex functions as both actin nucleator and branching protein [311]. Another 
eukaryotic protein, Villin, and a salmonella effector protein, Sip C, harbors an actin 
binding domain and an oligomerization domain and has been shown to bind and bundle 
F-actin [8, 314]. Plastin (Fimbrin), which harbors two actin binding domains, functions to 
bundle F-actin in microvilli [313]. Tarp orthologs also harbor one to several actin binding 
domains and a proline rich oligomerization domain. Moreover, the secondary structure 
of Tarp reveals additional α-helical domains similar to many other actin binding domains 
but has failed to bind G-actin in previous studies [64]. It is possible that these 
uncharacterized α-helices of Tarp specifically recognize F-actin to regulate cytoskeleton 
networks in addition to its nucleating capabilities. 
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1.3.5 Hypothesis 
We hypothesize that cytoskeleton reorganization required for entry of chlamydia 
is the product of co-operative activity of Tarp and Arp2/3 complex. Tarp nucleates 
monomeric actin to make the linear filamentous actin, which then serves as a substrate 
for Arp2/3 complex activity to generate a branching pattern of actin filaments usually 
observed in the microvillus tip. We also hypothesize that Tarp plays an additional role in 
modulating the filamentous actin network, which is independent of its actin nucleation 
ability. A complete understanding of Tarp mediated cytoskeletal changes is required to 
reveal the mechanisms by which Chlamydia invades the host tissue. 
  
48 
 
1.4 Figures and Tables 
 
 
Figure 1 Schematic representation of the mechanisms of induced phagocytosis 
by bacterial pathogens.  
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Figure 2 Schematic representation of pathophysiology and clinical manifestations 
of Listeriosis. 
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Figure 3 Diagrammatic representation of intracellular life cycle of L. 
monocytogenes. 
Key virulent proteins and stages involved are depicted as follows, InlA and Inl B 
required for invasion, Listeriolysin O and Phospholipases (A and B) for escape from 
vacuole, ActA for actin based intracellular motility and InlC for cell-cell dissemination. 
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Figure 4 Schematic representation of members of Internalin family expressed in 
L. monocytogenes.  
Important domains are represented in different colors. Signal peptide (Black box), 
Luciene rich repeat/LRR (green box), Inter-repeat/IR region (Yellow box), B domain (B), 
D domain (D) and surface anchors LPXXGD motif (Red box) or GW Domain (GWD). 
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Figure 5 Model for InlB mediated entry of L. monocytogenes.  
Met receptor is heterodimer consisting of extracellular alpha chain and a beta chain with 
extracellular, trans-membrane and intra-cytoplamic domain. Binding of InlB with Met 
receptor leads to dimerization and activation of Met receptors. Met gets auto 
phosphorylated at 1349 and 1356 tyrosine residues on the intra cytoplasmic domain. 
This results in recruitment of adaptor protein like Gab1. Gab1 causes recruitment of PI 
3-kinase resulting in its activation by Met and generation of lipid second messenger 
PIP3.  PI 3- kinase activity results in activation of Arp2/3 complex and F-actin 
recruitment by some unknown mechanism. 
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Figure 6 Chlamydiae taxonomy  
Based on recommendations from Chlamydia Basic Research Society meeting held in 
2009, Little Rocks, Arkansas, USA 
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Figure 7 Diagrammatic representation of developmental cycle of C. trachomatis. 
 Infectious elementary bodies (EB) enter host cells and remain confined in a membrane 
bound vacuole called inclusion. EB differentiate into metabolically active reticulate 
bodies (RB) which undergoes several rounds of replication. Following secondary 
differentiation RB reverts back to infectious EB. EBs gets released from the infected 
cells to start new infectious cycle. 
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Figure 8 Schematic representation of Tarp proteins from C. trachomatis serovar 
L2, D and A, C. pnuemoniae, C. caviae and C. muridarum. 
 Known domains of Tarp are represented by different colors as follows, N-terminal 
phosphorylation domain (green box), Proline rich oligomerization domain (blue box) and 
C-terminal Actin binding domains (red box). Number represents the amino acid present 
in Tarp polypeptide. Note that phosphorylation domain is present only in Tarp from 
trachoma species. Variable number of actin binding domain is found in Tarp orthologs 
from different chlamydial species. 
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Figure 9 Model for Tarp mediated entry of C. trachomatis. 
 EB translocate Tarp into host cell cytoplasm. Tarp directly polymerizes actin via its actin 
binding domain (red box) and proline rich oligomerization domain (blue box). Host cell 
kinase phosphorylates Tarp at its N-terminal phosphorylation domain (green box). 
Phosphorylated Tarp causes activation of Arp2/3 complex (pink circle) which further 
mediates actin polymerization. Together, this results in uptake of EB into host cells. 
Arp2/3 complex activation is also proposed to be mediated via signaling events 
occurring downstream to interaction of EB with unknown host cell surface receptors. 
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CHAPTER TWO: IDENTIFICATION OF COMPONENTS OF THE HOST 
TYPE 1A PI 3-KINASE PATHWAY THAT PROMOTES 
INTERNALIZATION OF LISTERIA MONOCYTOGENES 
 
2.1 Introduction  
 
Listeria monocytogenes is a food-borne bacterial pathogen capable of causing 
severe infections culminating in meningitis or abortion [61, 315]. Listeria induces its own 
internalization („entry‟) into host cells that are normally non-phagocytic. Entry of Listeria 
into enterocytes and hepatocytes plays an important role in virulence, by allowing 
bacteria to traverse the intestinal barrier and to colonize the liver [129]. Another 
potential role for Listeria internalization is infection of the placenta although this idea is 
controversial [316]. 
One of the major pathways of Listeria entry into host epithelial cells is mediated 
by interaction of the bacterial surface protein InlB with its host receptor, the Met receptor 
tyrosine kinase [61, 107]. InlB binds directly to the extracellular domain of Met, resulting 
in activation (tyrosine phosphorylation) of the receptor. Once activated, Met promotes 
signal transduction events that remodel the host cell surface, leading to bacterial 
engulfment [142, 143, 152, 153, 158]. Host surface remodeling is driven, at least in part, 
by localized polymerization of actin. One of the human signaling proteins that acts 
downstream of Met to stimulate F-actin assembly and internalization of Listeria is type 
IA phosphoinositide (PI) 3-kinase. Infection with Listeria induces localized activation of 
PI 3-kinase [142, 143]. Genetic or pharmacological inhibition of type IA PI 3-kinase 
results in a reduction in InlB-mediated actin polymerization and bacterial entry [130, 
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142, 143]. The molecular mechanism by which PI 3-kinase promotes internalization of 
Listeria is not known.  
One of the major pathways of Listeria entry into host epithelial cells is mediated 
by interaction of the bacterial surface protein InlB with its host receptor, the Met receptor 
tyrosine kinase [61, 107]. InlB binds directly to the extracellular domain of Met, resulting 
in activation (tyrosine phosphorylation) of the receptor. Once activated, Met promotes 
signal transduction events that remodel the host cell surface, leading to bacterial 
engulfment [142, 143, 152, 153, 158]. Host surface remodeling is driven, at least in part, 
by localized polymerization of actin. One of the human signaling proteins that acts 
downstream of Met to stimulate F-actin assembly and internalization of Listeria is type 
IA phosphoinositide (PI) 3-kinase. Infection with Listeria induces localized activation of 
PI 3-kinase [142, 143]. Genetic or pharmacological inhibition of type IA PI 3-kinase 
results in a reduction in InlB-mediated actin polymerization and bacterial entry [130, 
142, 143]. The molecular mechanism by which PI 3-kinase promotes internalization of 
Listeria is not known.  
Type IA PI 3-kinase is a heterodimeric enzyme comprised of a 110 kDa catalytic 
subunit and a 85 kDa regulatory subunit [317]. This PI 3-kinase controls a variety of 
processes in mammalian cells, including cell growth, survival, and motility. Type IA PI 3-
kinase promotes its biological effects through at least two mechanisms. The best 
understood mechanism involves lipid kinase activity. PI 3-kinase produces 
phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3], a lipid second messenger that 
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binds a plethora of downstream „target‟ proteins [317, 318]. PI(3,4,5)P3 recruits these 
target proteins to the plasma membrane, where they exert their biological activities. 
PI(3,4,5)P3 is converted by phosphatases to phosphatidlinositol 3,4-bis phosphate 
[PI(3,4)P2], another lipid with signaling activity [317, 318]. Apart from producing lipid 
second messengers, type IA PI 3-kinase can also regulate signal transduction through 
protein-protein interactions [147-149, 319].  
In order to understand how type IA PI 3-kinase promotes internalization of 
Listeria, it is critical to identify human proteins that act upstream and downstream of this 
kinase to control pathogen uptake. In this work, we describe an RNA interference 
(RNAi) –based genetic screen to identify components of the type IA PI 3-kinase 
signaling pathway involved in Listeria uptake. The 64 host genes targeted in this screen 
encode proteins that bind PI(3,4,5)P3 and/or PI(3,4)P2, proteins that interact with 
catalytic or regulatory subunits of PI 3-kinase, and proteins that are indirectly regulated 
by PI 3-kinase. Our findings indicate that at least nine human genes known to 
participate in type IA PI 3-kinase signaling are involved in entry of Listeria. This work is 
an important first step in dissecting the molecular mechanism by which type IA PI 3-
kinase mediates bacterial internalization. 
2.2 Material and Methods 
2.2.1 Bacterial Strains, Mammalian Cell Lines and Media 
The Listeria monocytogenes strain BUG 947 was used for these studies. 
BUG947 contains an in-frame deletion in the inlA gene, and has normal expression of 
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InlB [129]. Consequently, BUG 947 is incapable of infecting HeLa or other host cells 
through interaction of the Listeria surface protein InlA with its host receptor E-cadherin 
[61, 320]. Instead, this bacterial strain enters into host cells in an InlB-dependent 
manner [61, 142]. The Listeria strain was grown in brain-heart-infusion (BHI, Difco) 
broth and prepared for infection as described [130]. 
The human epithelial cell line HeLa (ATTC CCL-2) was grown in Dulbecco‟s 
Modified Eagle‟s medium (DMEM) with 4.5 g of glucose per liter and 2 mM glutamine 
(11995-065; Invitrogen), supplemented with 10% fetal bovine serum (FBS). Cell growth, 
cell stimulation, and bacterial infections were performed at 37˚C in 5% CO2. 
2.2.2 SiRNA 
Sequences of siRNAs used to target human genes comprising the host type IA 
PI 3-kinase pathway are listed in Table2.2. These siRNAs were designed by and 
purchased from Ambion. As negative controls, two „non-targeting‟ siRNAs were used. 
These control siRNAs (non-targeting control 1; Dharmacon cat. no. D-001210-01 or 
non-targeting control 2; Sigma-Aldrich cat. No. SIC001) contain two or more 
mismatches with all sequences in the human genome. Another control siRNA was 
directed against the nuclear gene lamin A/C (5‟-CUGAGAGCCGCAGCAGCUUtt-3‟). 
2.2.3 Antibodies, Inhibitors, and other Reagents 
Polyclonal antibodies used were anti-mTor (2972; Cell Signaling), anti-
phospholipase C-γ1 (sc-81; Santa Cruz Biotechnology), anti-Rab5c (HPA003426; 
Sigma-Aldrich), and anti-SWAP70 (sc-81991; Santa Cruz Biotechnology). The 
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monoclonal antibodies used were anti-GIT1 (611396; BD Biosciences), anti-PDK1 
(611070; BD Biosciences), anti-PSCD2 (ARNO) (clone 6H5; WH0009266M2; Sigma-
Aldrich), and anti-tubulin (T5168; Sigma-Aldrich). Secondary antibody horseradish 
peroxidase (HRPO) conjugates were from Jackson Immunolabs. 
2.2.4 Transfection of Hela Cells with SiRNA 
1.5 x 104 HeLa cells were seeded in wells of 24 well plates and grown for 
approximately 24 h. Transfection with siRNA and the lipid reagent LF2000 (Invitrogen) 
was as described [143]. In experiments in Figures 2.2-2.4, HeLa cells were transfected 
with pools of three different siRNA molecules for each target gene, except in the cases 
of ILK or HRAS. Targeting of ILK or HRAS involved transfection with a pool of two 
siRNAs or a single siRNA, respectively. The two or three siRNAs used in each pool are 
numbered as 1, 2, and 3 in Table 2.2. In the case of each siRNA pool (or of the HRAS 
single siRNA), the final total concentration of siRNA was 100 nM. Control conditions for 
the experiments in Figures 2-4 involved mock transfection in the absence of siRNA, 
transfection with 100 nM of either of two „non-targeting control‟ (NTC) siRNAs, and 
transfection with a siRNA directed against the lamin A/C gene. For experiments 
involving single siRNA molecules (Figure 2.5), siRNAs were used at a final 
concentration of 100 nM. Control experiments employing a 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) assay [321] indicated that control siRNAs or 
siRNA pools targeting each of the 64 target genes shown in Tables 2.1 and 2.2 did not 
affect viability of HeLa cells 48 h after transfection. 
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2.2.5 Real Time PCR Analysis 
 HeLa cells in 24 well plates were used for analysis of gene expression about 48 
h after transfection with siRNA. Cells were washed twice in PBS, and a TaqMan Gene 
Expression Cells to Ct kit (Applied Biosystems) was used to prepare cell lysates and 
cDNA. DNAse was included when making lysates in order to eliminate genomic DNA. In 
each experiment, a single sample of cells was used for each condition involving no 
siRNA, control siRNA, or siRNAs targeting a particular human gene. Real Time PCR 
was performed in triplicate on each cDNA sample using ABI7500 or ABI7900 
instruments (Applied Biosystems). TaqMan gene expression assays (probes) used for 
each of the 64 target genes comprising the human type IA PI 3-kinase pathway are 
listed in Table 2.2. Each of these probes spans exon-exon junctions, and should not 
detect genomic DNA. The GAPDH gene (gene expression assay Hs99999905_m1; 
Applied Biosystems) was used as an endogenous control. Threshold cycle (Ct) values 
for the 64 target genes ranged from 23-32 in the various experiments. Ct values for the 
GAPDH endogenous controls were typically between 18-19. Data was analyzed by the 
comparative Ct method [322], normalizing Ct values for target gene expression to those 
for GAPDH. Relative quantity (RQ) values were calculated by the formula RQ = 2-∆∆Ct. 
To obtain relative expression values in Figures 2.2-2.4, RQ values in a given 
experiment were normalized to the value in cells treated with non-targeting control 
siRNA 1 (NTC1). Relative expression values in Figure 2.5 were obtained by 
normalization to RQ values in cells mock transfected in the absence of siRNA („no 
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siRNA‟ condition). The data in Figures 2.2-2.5 are mean +/- SEM values from 3-7 
independent experiments, depending on the gene and siRNA condition. 
In the case of 10 out of the 64 human genes analyzed, expression could not be 
reliably detected using real time PCR and the available probe (Tables 2.2 and 2.3). In 
these situations, the Ct values obtained for the target genes ranged from 36 to 
undetectable. Control experiments with lysates that had not been subjected to reverse 
transcription yielded Ct values between 36 to undetectable for the various 64 genes. 
Based on these control experiments, any gene producing Ct values of 36 or greater, 
using reverse transcribed lysates, was considered to be expressed at levels too low for 
detection using the available probe. These genes were either not expressed in HeLa 
cells, expressed at levels below the limit of detection of real time PCR, or possibly 
incapable of being detected because of a flaw in probe design. 
2.2.6 Bacterial Entry Assays 
HeLa cells were used for bacterial infections approximately 48 hr after 
transfection with siRNA. Gentamicin protection assays to measure entry of Listeria 
(Figs. 11B, 12B, 13B, 14B) were performed by infecting for one h in the absence of 
gentamicin, and then incubating in DMEM with 20 µg/ml gentamicin for two h as 
described [61, 143]. Entry experiments involving HeLa cells transfected with siRNA 
pools (Figures 11-14) or single siRNAs (Figure 15) were performed 3-7 times, 
depending on the target gene. Entry efficiencies were first expressed as the percentage 
of the bacterial inoculum that survived gentamicin treatment. To obtain relative entry 
64 
 
values in Figures 11-13, absolute percent entry values in a given experiment were 
normalized to the value in cells treated with non-targeting control siRNA 1 (NTC1). 
Relative entry values in Figure 14 were obtained by normalization to percent entry 
values in cells mock transfected in the absence of siRNA („no siRNA‟ condition). 
2.2.7 Western Blotting and Immunoprecipitation 
Approximately 48 h after transfection with siRNA, HeLa cells were solubilized in 
RipA buffer (1% Triton X-100, 0.25% sodium deoxycholate, 0.05% SDS, 50 mM Tris-
HCl [pH 7.5], 2 mM EDTA, 150 mM NaCl, 1 mM PMSF, and 10 mg/L each of aprotinin 
and leupeptin). Western blots and detection using Enhanced Chemiluminescence (ECL) 
or ECL Plus reagents (GE Health Care) were performed as described [61, 130]. 
2.2.8 Statistical Analysis 
Statistical analysis was performed using Prism (version 5.0a; GraphPad 
Software). When comparing data from three or more conditions, ANOVA was 
performed. The Tukey-Kramer test was used as a post-test. A P value of 0.05 or lower 
was considered as significant. 
2.3 Results 
 
2.3.1 Construction of a SiRNA Library Targeting Components of the Type IA PI 3-
Kinase Pathway 
In order to better understand the mechanism of InlB-mediated internalization of 
Listeria, we used RNAi to target human genes encoding proteins that participate in type 
IA PI 3-kinase signaling. A literature search was performed to compile a list of 64 host 
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genes whose products are involved in signal transduction mediated by type IA PI 3–
kinase (Table 1). This list was then used to construct a short interfering RNA (siRNA) 
library, which was screened for effects on host target gene expression and Listeria 
entry. The human epithelial cell line HeLa was used for these studies, since this cell line 
is readily transfected, and has been extensively used to study InlB-mediated entry [143, 
152, 158, 323]. When assembling the list of genes to be targeted by RNAi, those 
encoding neuronal or lymphocyte-specific proteins unlikely to be expressed in HeLa 
cells were excluded. 
The human genes in the siRNA library were grouped in three categories, 
depending on the relationship of their protein products to type IA PI 3-kinase and its 
products PI(3,4,5)P3 and/or PI(3,4)P2 (Table 1 and Figure 10). A brief description of the 
categories follows. Category I contained 15 genes encoding proteins that are known to 
physically interact with catalytic and/or regulatory subunits of type IA PI 3-kinase. Some 
of these proteins, namely Ras GTPases, PI 3-kinase Interacting Protein 1, and 
PTK2/FAK control PI 3-kinase catalytic activity [324-326]. These proteins therefore act 
upstream of PI 3-kinase. Other proteins, for example Rab4 and Rab5 GTPases, have 
biochemical activities that are regulated by type IA PI 3-kinase [147]. These proteins 
might act downstream of the lipid kinase. For the remaining category I genes, 
insufficient information was available to propose where their protein products might act 
with regard to PI 3-kinase. Of these proteins, APPL and Cbl function at least partly as 
adaptor proteins [327-329] and their roles might lie in connecting the PI 3-kinase 
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pathway to other signaling pathways. Category II was comprised of 33 genes encoding 
proteins known to bind directly to PI(3,4,5)P3 and/or PI(3,4)P2. For most of these 
proteins, phosphoinositide binding is mediated by one or more Pleckstrin Homology 
(PH), Phox Homology (PX), or DHR1 domains [330] (Table 1). A few of category II gene 
products (e.g. GIT1, GIT2, SWAP70) bind PI(3,4,5)P3 through regions that are 
uncharacterized or that do not resemble other known protein-lipid interaction domains 
[331, 332]. Category III was composed of 16 genes whose products are indirectly 
regulated by type IA PI 3-kinase (Table 1). The scope of category III genes was not 
meant to be exhaustive. Instead, we focused on genes encoding substrates or effectors 
of some well-characterized direct targets of PI 3-kinase. Examples include isoforms of 
Protein Kinase C [333, 334], Protein Kinase N (substrates of the kinase PDK1) [315], or 
PAK kinases (substrates of PDK1) [335] and mTor (a kinase indirectly regulated by Akt 
proteins) [336]. 
2.3.2 RNAI Based Screen 
siRNAs were designed that target the 64 genes encoding components of the type 
IA PI 3-kinase pathway (Table 2). For the vast majority of these genes (62 of 64), three 
different siRNAs were made and combined into pools to test for effects on host target 
gene expression and Listeria entry. In the case of the gene ILK, a pool of two siRNAs 
was used. The rationale for using a pooling approach was that screening multiple 
siRNAs together might increase the probability of effectively silencing target gene 
expression in situations in which not all of the individual siRNAs are potent. In the case 
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of one of the host genes (HRAS), only one siRNA was used. This latter siRNA 
effectively inhibited gene expression (see below). 
siRNA pools (or a single siRNAs for HRAS) were transfected into HeLa cells. As 
controls, cells were mock transfected in the absence of siRNA or transfected with a 
control „non-targeting‟ siRNA (referred to as „NTC1‟) that has two or more mismatches 
with all known human mRNA transcripts. Approximately 48 hr post-transfection, gene 
expression was assessed by real time PCR (Materials and Methods). Of the 64 genes 
selected for analysis, 47 displayed a statistically significant reduction in gene expression 
by targeting siRNAs, compared to the control conditions (Figs. 11A, 12A, and 13A). For 
10 of the 64 genes, expression could not be reliably detected by real time PCR using 
the available probes (Table 3). Effective antibodies against the product of one of these 
genes, PLC-γ1, was commercially available. Western blotting indicated depletion of 
PLC-γ1 protein (Fig. 12Aii). In the case of eight of the genes targeted, expression was 
detected by real time PCR, but siRNA pools targeting these genes did not reduce 
expression (Table 3). In summary, out of the 64 genes initially selected for silencing, 47 
exhibited substantial RNAi-mediated reduction in expression at the mRNA or protein 
level. None of the siRNA conditions targeting these 47 genes affected cell growth or 
viability, as assessed by MTT assays [321] (data not shown).  
The 47 genes whose expression was inhibited by siRNA were also examined for 
roles in Listeria entry. Internalization of Listeria into transfected HeLa cells was 
measured by gentamicin protection assays, in parallel with the gene expression studies 
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(Figs. 11B, 12B, 13B). Control conditions for the entry experiments included the 
absence of siRNA and NTC1 siRNA, used in the gene expression analysis. Additional 
controls were another non-targeting siRNA (NTC2) and a siRNA capable of silencing 
the nuclear protein lamin A/C. Compared to the controls, siRNAs against 21 of the type 
IA PI 3-kinase pathway genes resulted in statistically significant changes in entry of 
Listeria (Figs. 11B, 12B, 13B). For 19 of these genes, siRNAs reduced entry, 
suggesting a positive role in bacterial uptake. The extent of inhibition in entry ranged 
from ~ 70 to 95%, depending on the host gene targeted. As a reference, under the 
same cell growth and control transfection conditions, a bacterial mutant deleted for the 
inlB gene enters into HeLa cells at about a 90% reduced frequency compared to the 
isogenic inlB-positive strain [323]. In the case of two of the human genes targeted in the 
RNAi screen (KRAS2 and DOCK1), siRNAs augmented the efficiency of internalization, 
consistent with a negative role. The 21 host genes implicated in bacterial entry encode 
three proteins that bind to catalytic or regulatory subunits of PI 3-kinase (Fig. 11), 
twelve proteins that interact with PI(3,4,5)P3 and/or PI(3,4)P2 (Fig. 12), and six proteins 
that are indirectly regulated by PI 3-kinase (Fig. 13). Collectively, the gene expression 
and bacterial entry results in Figures 11-13 indicate that several members of the type IA 
PI 3-kinase pathway play important roles in InlB-mediated internalization of Listeria. In 
the Discussion section, we comment on known cellular functions of key host proteins 
that emerged from the RNAi screen. Also discussed are possible mechanisms by which 
some of the PI 3-kinase pathway proteins might promote entry of Listeria. 
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2.3.3 Addressing Possible Off-Target Effects of SiRNAs 
Although RNAi is a powerful method of genetic analysis, a potential weakness of 
this approach is the occurrence of „off-target‟ effects [337]. „Off-target‟ refers to a 
situation in which an siRNA affects an mRNA apart from the desired target mRNA [337]. 
One common method of minimizing the possibility of off-target effects is to confirm that 
several different siRNA molecules recognizing distinct regions in a given mRNA cause 
the same biological phenotype[337]. We selected eight of the 21 human genes 
implicated in Listeria entry (Figures 11-13), and tested whether multiple siRNAs 
inhibiting target gene expression also impaired bacterial uptake. The genes selected 
were the category I gene RAB5C, category II genes PSCD1, DAPP1, GIT1, PDPK1, 
and SWAP70, and category III genes FRAP1 and PRKCZ. The multiple siRNAs used 
consisted of the three individual components of the siRNA pools employed in 
experiments in Figures 11-13. In some cases (e.g. PDPK1 and FRAP1), a fourth siRNA 
was also tested. Data are presented in Figure 14. Importantly, for each of the eight 
selected genes, three siRNAs of unique sequence inhibited both bacterial entry and 
gene expression at the mRNA level. For five out of these eight human genes, effective 
antibodies were commercially available. We used these antibodies to confirm inhibition 
of expression at the protein level (Fig. 15). Altogether, the findings in Figures 14 and 15 
indicate that off-target effects for the eight selected host genes are unlikely. The data 
support the idea that these genes have bona-fide roles in Listeria internalization.  
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In previous work, we confirmed that multiple siRNAs targeting the human 
CENTD1 gene (encoding the protein ARAP2) impair gene expression at the mRNA and 
protein level, and also block Listeria entry [323]. Based on the present study and 
previous work, we conclude that our RNAi-based screen has identified at least nine 
human genes that are required for efficient InlB-mediated entry of Listeria. 
2.4 Discussion 
 
In this work, we describe an RNAi screen that led to the identification of at least 
nine human genes encoding proteins in the type IA PI 3-kinase pathway that play 
important roles in entry of Listeria. One of the genes identified from the screen, RAB5C, 
codes for a protein that interacts with regulatory and catalytic subunits of type IA PI 3-
kinase [147-149]. Six of the host genes, CENTD1, PSCD2, DAPP1, GIT1, PDPK1, and 
SWAP70, encode proteins that bind directly to the PI 3-kinase lipid products PI(3,4,5)P3 
and/or PI(3,4)P2 [331, 332, 338-341]. Two of the genes identified from the screen, 
FRAP1 and PRKCZ, code for proteins that are indirectly regulated by PI 3-kinase [338, 
342, 343]. In addition to the nine host genes described above, it seems likely that other 
members of the type IA PI 3-kinase signaling pathway are involved in InlB-dependent 
entry of Listeria. Results with siRNA pools implicated 21 different human genes in 
bacterial internalization (Figs. 11-13). Nine of these 21 genes were further examined for 
roles in Listeria entry by testing multiple individual siRNAs (Fig. 14). The results 
indicated that off-target effects were unlikely, and that the nine host genes therefore 
have important roles in bacterial uptake. Future work using single siRNAs will determine 
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which of the remaining 12 host genes have bona fide functions in Listeria entry. 
In the case of 26 of the host genes targeted in our study, siRNA-mediated 
inhibition in expression failed to affect Listeria entry in a statistically significant fashion. 
These findings suggest that many of these 26 genes do not have important roles in 
bacterial internalization, at least not in the conditions employed in our work. It is worth 
noting that two of these 26 human genes, PLD2 and CBL, have been previously 
implicated in InlB-mediated uptake. In the case of PLD2, an earlier study used a cell line 
other than HeLa [344]. The apparent discrepancy between our data and this prior study 
is most likely due to cell line differences. Previous siRNA studies targeting CBL in HeLa 
cells suggested that this host gene was needed for efficient Listeria entry [158]. In our 
work, siRNAs directed against CBL reduced internalization of Listeria by approximately 
70%, but the effect was not statistically significant.  
As described above, our RNAi screen identified at least nine human genes that 
have important functions in InlB-mediated entry. How might these genes control 
internalization of Listeria? Below, we describe what is known about the cellular functions 
of the protein products of the genes. Molecular mechanisms by which these proteins 
might regulate bacterial entry are discussed below. 
Rab5c. Rab5c is one of three Rab5 GTPases that control clathrin-dependent 
endocytosis and early endosome fusion [345]. Results from the RNAi-based screen 
indicated a role for Rab5c, but not Rab5a or Rab5b proteins, in Listeria entry (Figs. 11, 
14, 15). Activated Rab5 proteins bind to the p110 catalytic and p85 regulatory subunits 
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of type IA PI 3-kinase [147, 149, 346]. Interaction of Rab5 proteins with p85 results in 
enhanced GTP hydrolysis on Rab5 [346]. These findings suggest that PI 3-kinase might 
control Rab5-mediated endocytosis and/or subsequent vesicular trafficking. Importantly, 
InlB-dependent entry of Listeria requires clathrin and several other human proteins that 
regulate clathrin-mediated endocytosis [158]. It is possible that Rab5c works together 
with the endocytic machinery previously reported to control Listeria uptake. How might 
Rab5-dependent endocytosis promote bacterial entry? Recent results indicate an 
important role for Rab5 in signal transduction and actin polymerization mediated by the 
Met receptor [347]. Activation of Met by its mammalian ligand Hepatocyte Growth 
Factor (HGF) leads to the Rab5-dependent stimulation of the GTPase Rac1 and 
subsequent actin polymerization. Rab5 promotes internalization of Rac1 into 
endosomes, where Rac1 is then activated. Activated, endosomal Rac1 is then delivered 
to specific sites on the plasma membrane, resulting in cortical actin polymerization. 
Importantly, Rac1 is needed for InlB-mediated internalization of Listeria [153]. The 
recent findings with Rab5 and Met raise the possibility that one role of Rab5c in Listeria 
entry might be to facilitate the localized delivery of Rac1 to promote subsequent 
cytoskeletal remodeling. 
Regulators of Arf GTPases (ARAP2, GIT1, ARNO). Results from the RNAi-
based screen indicated that at least six host genes encoding proteins that bind 
PI(3,4,5)P3 have important functions in internalization of Listeria. Three of these host 
proteins, ARAP2 (encoded by CENTD1), GIT1, and ARNO (encoded by PSCD2), are 
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regulators of small GTPases of the Arf family [348]. ARAP2 and GIT1 are GTPase 
Activating Proteins (GAPs) capable of antagonizing various Arf GTPases [348]. Binding 
of PI(3,4,5)P3 to ARAP2 or GIT1 enhances the GAP activities of these proteins [332, 
341]. These findings indicate that type IA PI 3-kinase can inhibit Arf GTPases through 
ARAP2 and GIT1. In previous work, we found that ARAP2 promotes entry of Listeria, in 
part, by restraining the activity of Arf6 [323]. The mechanism by which ARAP2-mediated 
inhibition of Arf6 facilitates bacterial uptake is not known. The observation that 
uncontrolled activation of Arf6 leads to sequestration of cholesterol and PI(4,5)P2 in 
internal membranes [349, 350] prompted an hypothesis that ARAP2 might maintain the 
normal plasma membrane localization of lipids critical for Listeria uptake [323].  Like 
ARAP2, it is possible that GIT1 promotes internalization of Listeria by antagonizing Arf6. 
This idea would imply that neither ARAP2 nor GIT1 alone is sufficient to fully inactivate 
Arf6. Alternatively, GIT1 could act through regulation of other Arf GTPases, such as 
Arf1, Arf2, Arf3, or Arf5 [332, 351]. A third way that GIT1 could mediate Listeria uptake 
is by contributing to the activation of Rac1 and/or Cdc42 GTPases. Both Rac and 
Cdc42 are needed for InlB-mediated entry [152, 153]. GIT1 promotes the activation of 
these two GTPases by binding to the guanine nucleotide exchange factor (GEF) α-PIX 
[351, 352]. ARNO, the third Arf regulator identified in our RNAi screen, is a GEF that 
activates Arf1 or Arf6 GTPases [348]. PI(3,4,5)P3 binds to a pleckstrin homology (PH) 
domain in ARNO, thereby recruiting this GEF to the plasma membrane [340, 348]. In 
previous work, we found that siRNA-mediated depletion of Arf6 did not impair Listeria 
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entry [323]. This finding indicates that ARNO does not mediate bacterial internalization 
through Arf6. It is possible that ARNO acts on Arf1 to stimulate Listeria uptake. 
Experiments involving RNAi-mediated depletion of Arf1 indicate an important role for 
this GTPase in InlB-mediated bacterial entry (P. Le and K. Ireton, unpublished data). 
Arf1 could control entry by promoting PI(4,5)P2 synthesis through PI 4-phosphate 5-
kinase [348]. Alternatively or additionally, ARNO might stimulate Listeria uptake by 
promoting recycling of integrin receptors to the plasma membrane [353]. Integrins 
contribute to signaling downstream of the Met receptor [354], and are also needed for 
efficient InlB-mediated entry of Listeria [355]. 
SWAP70. Another PI(3,4,5)P3 –interacting protein that is required for Listeria 
entry is SWAP70, a known direct activator of Rac1 GTPase [331]. As previously 
mentioned, Rac1 promotes InlB-mediated entry by eliciting actin cytoskeletal changes 
through the Arp2/3 complex [152, 153]. SWAP70 is a Rac1 GEF whose activity is 
stimulated by PI(3,4,5)P3 [331]. Our findings suggest that Rac1 activation downstream 
of the Met receptor during Listeria entry might be promoted by SWAP70. Apart from 
SWAP70, our RNAi-based screen targeted several other PI(3,4,5)P3 –regulated GEFs 
for Rac1. The results indicated that the GEFs Dock180, SOS1, and Vav2 are 
dispensable for internalization of Listeria (Fig. 12).  
DAPP1. The DAPP1 gene is critical for Listeria entry and encodes a PI(3,4,5)P3 
–binding adaptor protein. DAPP1 protein contains a PH domain that interacts with 
PI(3,4,5)P3, an SH2 domain, and a tyrosine residue capable of being phosphorylated 
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[356, 357]. Known functions of DAPP1 include regulation of phospholipase C-γ1 and 
activation of Rac1 GTPase [356, 358]. The lack of a recognizable GEF domain in 
DAPP1 indicates that the effect on Rac1 activity is likely indirect. Our RNAi data 
suggested an important role for phospholipase C-γ1 in InlB-mediated entry (Fig. 12). 
Possible ways that DAPP1 could promote Listeria uptake include activation of PLC-γ1 
and/or Rac1. 
PDK1 and PKC-ζ. Results from the RNAi screen indicated important functions 
for the serine/threonine kinase PDK1 (encoded by the PDPK1 gene) in Listeria entry. 
PDK1 is a „master kinase‟ that phosphorylates the activation loop of more than 20 
serine/threonine kinases of the AGC family [334, 338]. PDK1-mediated phosphorylation 
is critical for the activity of these AGC kinases. Our siRNA library targeted 13 genes 
encoding AGC kinases that are PDK1 substrates (Table 1). Eight of these 13 genes 
were expressed in HeLa cells and effectively silenced by siRNA (Fig. 13; Table 2). 
These eight genes were Akt1, Akt2, PRKCD (encoding PKC-δ), PRKCG (encoding 
PKC-γ), PRKCZ (encoding PKC-δ) PKN1, PKN2, and SGK1. Results with siRNA pools 
suggested that PRKCD, PRKCZ, PKN1, and PKN2 might have important functions in 
Listeria internalization. Experiments with single siRNAs confirmed that PRKCZ plays a 
crucial role in InlB-mediated entry. Importantly, the product of PRKCZ, PKC-δ is known 
to regulate the actin cytoskeleton [356, 359, 360]. Potential substrates of PKC-δ include 
proteins that cross link F-actin to the plasma membrane (MARCKs and ERM proteins), 
actin binding proteins of the coronin family, the actin capping protein adducin, the actin 
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bundling protein fascin, and the anti-capping protein VASP [333, 361]. PKC-δ could 
mediate entry of Listeria, at least in part, by stimulating actin remodeling through 
phosphorylation of one or more of these substrates. Another important activity of PKC-δ 
is in promoting exocytosis- the fusion of intracellular vesicles with the plasma 
membrane [360, 362]. Specifically, PKC-δ phosphorylates VAMP2, a vesicular protein 
that mediates vesicle docking to the plasma membrane [363]. Thus far, a role for 
exocytosis in entry of Listeria has not been described. During Fc-γ receptor-mediated 
phagocytosis in macrophages, exocytic delivery of vesicles to the phagosome 
replenishes membrane that would be otherwise lost due to particle internalization [364]. 
It is possible that exocytosis occurs during Listeria uptake and serves a similar function. 
Another potential function for exocytosis could be to provide membrane needed for 
extension of pseudopods around adherent bacteria.  
mTor. The RNAi screen revealed a critical role for the host protein mTor in InlB-
mediated entry of Listeria. mTor (encoded by the FRAP1 gene) is a serine/threonine 
kinase that functions downstream of type IA PI 3-kinase to regulate several biological 
processes, including translation, ribosome biogenesis, autophagy, and cytoskeletal 
organization [336, 343]. mTor is present in two different multi-protein complexes termed 
mTORC1 and mTORC2. mTORC1 controls protein synthesis, cell growth, and 
autophagy. In contrast, mTORC2 regulates the actin cytoskeleton. Many of the cellular 
functions of mTORC1 are inhibited by the drug rapamycin [343], whereas mTORC2 is 
thought to be insensitive to this compound. Interestingly, treatment of HeLa cells with 
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rapamycin fails to impair InlB-mediated internalization of Listeria (data not shown), 
suggesting that the mTor complex involved in bacterial uptake is likely mTORC2, and 
not mTORC1. mTORC2 is known to control the actin cytoskeleton through 
phosphorylation of Protein Kinase C (PKC)-α or activation of Rac1 GTPase [336]. 
Future work will determine whether mTor promotes internalization of Listeria through 
PKC-α, Rac1, or via a previously unrecognized pathway. 
The RNAi-based screen described in this work represents a key first step 
towards understanding how type IA PI 3-kinase promotes InlB-mediated entry of 
Listeria. Future studies will examine the molecular mechanisms by which the proteins 
encoded by the various host genes identified in the screen control Listeria uptake. Such 
work will contribute to a better understanding of how bacterial activation of the Met 
receptor elicits actin cytoskeletal changes that drive Listeria internalization. Future 
studies on human proteins identified from the screen also have the potential to uncover 
novel host cell events needed for bacterial entry, such as localized exocytosis.  
Importantly, human type IA PI 3-kinase plays a critical role in internalization of 
several microbial pathogens apart from Listeria. Such microbes include bacterial 
pathogens that cause anthrax (Bacillus anthracis) [365], respiratory infections 
(Pseudomonas aeruginosa and Chlamydia pneumoniae) [366], and food-borne disease 
(Campylobacter jejuni and Yersinia enterolitica) [367, 368]. Host type IA PI 3-kinase 
also promotes entry of Ebola virus [369], and parasites causing Chagas‟ disease 
(Trypanosoma cruzi) [370] or toxoplasmosis (Toxoplasma gondii) [371]. To the best of 
78 
 
our knowledge, our work is the first systematic study to identify components of the host 
type IA PI-3 kinase pathway involved in infection by a microbial pathogen. Human 
proteins identified as critical for Listeria entry may also be viable candidates for host 
factors mediating infection by these other important pathogens. 
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2.5 Figures and Tables 
 
 
 
 
 
Figure 10 Human type 1A PI 3-kinase pathway components targeted in the RNAi 
based screen. 
 During infection with Listeria, host type IA PI 3-kinase is activated downstream of the 
Met receptor and plays a critical role in bacterial internalization [130, 142, 305]. Type IA 
PI 3-kinase uses PI(4,5)P2 as a substrate and produces the lipid second messenger 
product PI(3,4,5)P3 (9, 28). PI(3,4)P2 is another second messenger that is generated 
from PI(3,4,5)P3 by phosphatases [318]. The RNAi-based screen performed in this 
study targeted three categories of host genes encoding proteins that act on the type IA 
PI 3-kinase signaling pathway. Category I genes encode proteins that interact with the 
85 kDa regulatory and/or 110 kDa catalytic subunits of PI 3-kinase. Category II genes 
code for proteins that bind to the PI 3-kinase lipid products PI(3,4,5)P3 and/or PI(3,4)P2. 
Category III genes encode products that are indirectly controlled by type IA PI 3-kinase. 
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Table 1 Genes targeted in SiRNA library 
 
 
     References: [147, 324-329, 372] 
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      Reference:[332, 338, 340, 341, 351, 373-377] 
  
82 
 
 
     References: [331, 348, 357, 378-386] 
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Figure 11 Effect of SiRNA targeting category 1 host genes on gene expression 
and InlB mediated entry of Listeria. 
 (A). Inhibition of host gene expression by siRNA pools. HeLa cells were transfected 
with siRNA pools targeting the indicated host category I genes. As controls, cells were 
transfected with a non-targeting control siRNA (NTC1) or mock transfected in the 
absence of siRNA (none). Approximately 48 hr after transfection, cells lysates were 
prepared. Gene expression was analyzed by real time PCR. Relative gene expression 
values were determined as described in the Materials and Methods. Data are mean +/- 
SEM of 3-5 experiments, depending on the siRNA condition. Statistical analysis by 
ANOVA indicated P < 0.0001. *, P < 0.05 relative to the NTC1 or no siRNA controls 
(Tukey-Kramer post-test). (B). Impact of siRNA pools on internalization of Listeria into 
host cells. HeLa cells were transfected with siRNA pools directed against the indicated 
host category I gene. As controls, cells were transfected with either of two non-targeting 
control siRNAs (NTC1, NTC2), a siRNA directed against lamin A/C, or mock transfected 
in the absence of siRNA (none). About 48 hr post-transfection, bacterial entry was 
assessed using gentamicin protection assays. Relative entry values were obtained by 
normalizing to entry in cells treated with the NTC1 control, as described in the Materials 
and Methods. Data are mean +/-SEM values. Results for siRNAs targeting category I 
genes are from 3-7 experiments, depending on the siRNA condition. Data with the no 
siRNA (none), NTC2, or lamin A/C siRNA control conditions are from 46, 13, or 13 
experiments, respectively. Statistical analysis by ANOVA indicated P < 0.0001. *, P < 
0.05 relative to the NTC1, NTC2, lamin A/C, or no siRNA controls (Tukey-Kramer post-
test). 
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Figure 12 Effect of SiRNA s directed against category II host genes on gene 
expression and Listeria internalization. 
 (A). Inhibition of host gene expression. HeLa cells were transfected with siRNA pools 
targeting the indicated host category II genes. Control transfection conditions and 
analysis of gene expression were as described in the legend for Fig. 2. Data are mean 
+/- SEM of 3-5 experiments, depending on the siRNA condition. Statistical analysis by 
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ANOVA indicated P < 0.0001. *, P < 0.05 relative to the NTC1 or no siRNA controls 
(Tukey-Kramer post-test). (B). Effect of siRNA pools on internalization of Listeria. HeLa 
cells were transfected with siRNA pools directed against the indicated host category II 
gene. Control transfection conditions and measurement of bacterial entry was as 
described in the legend for Fig. 2. Data involving siRNAs targeting category II genes are 
mean +/-SEM of 3-5 experiments. Data with the no siRNA (none), NTC2, or lamin A/C 
siRNA control conditions are from 46, 13, or 13 experiments, respectively. Statistical 
analysis by ANOVA indicated P < 0.0001. *, P < 0.05 relative to the NTC1, NTC2, lamin 
A/C, or no siRNA controls (Tukey-Kramer post-test). 
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Figure 13 Effect of SiRNA targeting category III host genes on gene expression 
and Listeria internalization. 
 (A). Inhibition of host gene expression. HeLa cells were transfected with siRNA pools 
targeting the indicated host category III genes. Control transfection conditions were as 
described in the legend for Fig. 2. Gene expression was analyzed by real time PCR for 
all but one of the genes (i). In the case of PLCG1 (encoding PLC-
expression was assessed by Western blotting (ii), since the probe did not detect 
expression (Materials and Methods). For experiments involving siRNAs targeting 
category III genes, data are mean +/- SEM values of 3-5 experiments, depending on the 
siRNA condition. Statistical analysis by ANOVA indicated P < 0.0001. *, P < 0.05 
relative to the NTC1 or no siRNA controls (Tukey-Kramer post-test). (B). Impact of 
siRNA pools on entry of Listeria. HeLa cells were transfected with siRNA pools directed 
against the indicated host category III genes. Control transfection conditions and 
measurement of bacterial entry were as described in the legend for Fig. 2. Data with 
siRNAs targeting category III genes are mean +/- SEM of 3-7 experiments. Data with 
the no siRNA (none), NTC2, or lamin A/C siRNA control conditions are from 46, 13, or 
13 experiments, respectively. Statistical analysis by ANOVA indicated P < 0.0001. *, P < 
0.05 relative to the NTC1, NTC2, lamin A/C, or no siRNA controls (Tukey-Kramer post-
test). 
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Figure 14 Multiple SiRNA inhibiting target gene expression impairs internalization 
of Listeria. 
 HeLa cells were transfected with siRNA pools or individual siRNAs targeting the human 
gene indicated in A-H. Four individual siRNAs were tested for PDPK1 and FRAP1, 
whereas three siRNAs were tested for all other genes. As controls, cells were mock 
transfected in the absence of siRNA (no siRNA) or transfected with control non-
targeting siRNA 1 (NTC1). (i). Effect of siRNAs on host gene expression. Gene 
expression was analyzed by real time PCR. Data are mean +/- SEM of 3-4 experiments, 
depending on the siRNA condition. ANOVA indicated P <  0.0001 for Rab5c (A), PDPK1 
(E), SWAP70 (F), FRAP1 (G), and PRKCZ (H), P = 0.0001 for GIT1 (D), P = 0.0003 for 
DAPP1 (C), and P = 0.0012 for PSCD2. *, P < 0.05 relative to the no siRNA or NTC1 
controls (Tukey-Kramer post-test). (ii). Effect of siRNA pools on internalization of 
Listeria. Data are mean +/- SEM of 3-7 experiments, depending on the siRNA condition. 
Statistical analysis by ANOVA indicated P < 0.0001 for all data in A-H. *, P < 0.05 
relative to the no siRNA or NTC1 controls (Tukey-Kramer post-test) 
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Figure 15 Confirmation that SiRNA inhibits expression at protein level. 
 Human proteins evaluated for expression are indicated on the left. Gene names are 
given in parentheses.  HeLa cells were transfected with siRNA pools (P) or individual 
siRNAs directed against the indicated human gene. As controls, cells were either mock 
transfected in the absence of siRNA (-) or transfected with non-targeting control 1 
siRNA (C). Approximately 48 hr after transfection, cells were solubilized in RipA buffer. 
The indicated target protein was detected by Western blotting as described in the 
Materials and Methods. In order to confirm equivalent loading, membranes were then 
stripped and probed a second time with anti-tubulin antibodies.  
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2.6 Supplemental Information 
 
Table 2 siRNA and probe for measuring gene expression 
 
 
93 
 
 
94 
 
 
95 
 
 
96 
 
 
97 
 
Table 3 Human genes whose expression was not detected by real time PCR or 
failed to be inhibited by siRNA 
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CHAPTER THREE: CHLAMYDIA TRACHOMATIS TARP COOPERATES 
WITH THE ARP2/3 COMPLEX TO INCREASE THE RATE OF ACTIN 
POLYMERIZATION 
 
3.1 Introduction 
 
C. trachomatis, a gram negative obligate intracellular pathogen, is responsible for 
the most common sexually transmitted disease in the United States. It also causes 
trachoma, which is the most common form of preventable blindness in underdeveloped 
countries [397]. Chlamydia exhibits a unique developmental cycle that alternates 
between the extracellular infectious and metabolically inactive form, the elementary 
body (EB), and the intracellular non-infectious replicative form, the reticulate body (RB) 
[162]. Being an obligate intracellular organism, gaining access into the host cell is the 
most critical step in survival of C. trachomatis. Upon internalization, the EB transforms 
into a RB, which then undergoes several rounds of replication before reverting back to 
infectious EB [162].  
Chlamydia induces its uptake so efficiently that the process has been 
distinguished as “parasite- specified phagocytosis.” The uptake of an EB involves its 
attachment to the host cell surface followed by its entry [162, 297]. The initial step in the 
attachment is the reversible electrostatic interaction of the EB with the host cell surface. 
There is much evidence to suggest the role of heparan sulfate proteoglycans in such an 
interaction in many, if not all, strains of C. trachomatis [228, 278]. Studies employing 
defective mutants of CHO cell lines suggest a second irreversible step of attachment 
occurring before entry [236]. Despite considerable efforts, neither the chlamydial ligands 
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nor the host cell surface receptors critical for such irreversible interactions have yet to 
be identified. Although several putative host receptors have been suggested, including 
PDGF-β R and FGFR, blocking of these receptors only partially inhibited entry [237, 
238]. This suggests that irreversible attachment involves multiple interactions of the EB 
with the host cell surface. While the molecular mechanism of attachment remains 
undefined, the post-attachment events of chlamydial invasion have begun to be 
characterized.  
Like many other intracellular bacteria, the entry of chlamydia is also driven by the 
rearrangement of the host actin cytoskeleton [292]. The attachment of an EB to the host 
cell surface results in the recruitment of actin, and the treatment of host cells with 
inhibitors of actin polymerization, such as cytochalasin D, inhibits chlamydial entry [292].  
Efficient entry of chlamydia requires active participation of both the host and chlamydial 
proteins. Activation of the Arp2/3 complex, a host actin nucleator, is a critical event in 
regulating actin dynamics during chlamydial entry as the disruption of Arp2/3 complex 
activation abrogates entry [296, 299]. Upon entry of C. Trachomatis, Arp2/3 complex is 
regulated via activation of Rac GTPases, which in turn are regulated via host signaling 
[296, 299]. Because the surface receptor essential for chlamydial entry is not known, 
the signaling events that result in activation of Rac GTPases have remained elusive for 
the most part. It is believed that multiple mechanisms are involved in activation of 
Arp2/3 complex. Some bacterial effector proteins are also known to regulate Arp2/3 
complex either by direct binding and activation of the Arp2/3 complex or by manipulating 
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the activity of Rho family GTPases [63, 95]. No chlamydial effectors are yet identified 
that can directly interact with Arp2/3 complex. However, controversial evidences do 
exist regarding the indirect regulation of Arp2/3 by a chlamydial effector protein Tarp 
[296, 306]. 
Chlamydia also mediates its entry by a second mechanism involving its type III 
effector protein called Tarp [64, 243, 307]. Tarp, which stands for translocated actin 
recruiting protein, is conserved among all pathogenic species of chlamydia [306]. EBs 
deliver pre-synthesized Tarp into the host cytoplasm following its initial attachment 
[243]. In vitro functional analysis of Tarp demonstrated its ability to polymerize actin 
[64]. Such capacity is attributed to the presence of a C-terminal actin binding domain 
(ABD) and a proline rich oligomerization domain (PRD), which clusters multiple actin 
monomers to nucleate new actin filaments. Chlamydial EBs showed reduced invasive 
capacity in host cells that were microinjected with neutralizing antibodies that target 
ABD [307]. This implicates the bona fide role of Tarp in chlamydial entry. 
Tarp harbors an additional N-terminal phosphorylation domain, which consists of 
a variable number of tyrosine rich repeats of ~50 amino acids, with LGV serovars 
harboring 6 and the trachoma group harboring 3 such repeats [306]. Tarp becomes 
phosphorylated at several tyrosine residues by Src, Abl and Syk kinases immediately 
following its translocation into the host cell [237, 309]. The phosphorylated Tarp remains 
in close association with the developing inclusion [243]. However, the significance of 
such associations is not completely understood. Recently, the interaction of 
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phosphorylated Tarp with SH2 domain containing adaptor protein SHC1 and PI-3 
kinase became evident [312, 398]. The association of Tarp with SHC1 has been linked 
with survival of the infected host, which is essential for inclusion development [398]. As 
far as the role of the phosphorylation domain in entry is concerned, the effect of such 
phosphorylation on Tarps ability to nucleate actin is not yet known. Previous studies 
employed an unphosphorylated form of recombinant Tarp to investigate its role in actin 
dynamics [64, 307]. Since Tarp naturally exists in phosphorylated form within the host 
cytoplasm, it is essential to test if phosphorylation enhances or hampers Tarps ability to 
nucleate actin. While the possibility of Tarp or phosphorylated Tarp interacting directly 
with Arp2/3 complex to cause its activation has never been tested, controversial 
evidence does exist linking the phosphorylated Tarp with Arp2/3 complex activation. 
Lane et al suggested participation of the phosphorylation domain in activation of Rac 
GTPases via recruitment of GEF complexes including Sos/Abi/Aps8 and Vav2 [312]. 
Interestingly, another study suggested that Tarp phosphorylation is not necessary for 
the invasion of EBs as the prevention of Tarp phosphorylation had no effect on entry 
[306, 309]. Moreover, the phosphorylation domain is not conserved in other chlamydial 
species other than C. Trachomatis, even though invasion is critical for the survival of all 
species [306]. This implies that either the phosphorylation domain is not essential in 
entry of C. trachomatis, or that other species have evolved other mechanisms of 
initiating signaling events. Regardless of our lack in knowledge about exact signaling 
events, Tarp and Arp2/3 complex are both required for efficient entry of chlamydia. 
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Whether these two nucleators play an independent role in entry or if they cooperate in 
regulating the actin dynamics is not yet known.  
In this study, we first reconfirmed the role of Arp2/3 complex in chlamydial entry 
using two newly identified Arp2/3 inhibitors, CK-666 and CK-869. We also provide the 
first bio-chemical evidence that Tarp and Arp2/3 complex cooperate to form a branched 
network of actin filaments, which might be necessary for entry of chlamydia, and that 
phosphorylation of Tarp has no effect on its cooperative activity with Arp2/3 complex. 
And importantly, we provide evidence that Tarps ability to recruit actin is independent of 
its phosphorylation domain. 
3.2 Material and Methods 
3.2.1 Invasion Assay 
Chlamydia trachomatis invasion of HeLa cells was determined as previously 
described using fluorescently labeled elementary bodies (EBs) [296]. Briefly, to 
determine the percent of internalized C. trachomatis elementary bodies in drug treated 
cells, HeLa 229 (ATCC) host cells were pretreated for 1.5 hours with the recently 
characterized Arp2/3 chemical inhibitors CK-869 and  CK-666 (Calbiochem) and 
infected with CellTrackerTM  CMTPX (Invitrogen) labeled C. trachomatis L2 (MOI ~30) 
[399]. Two inactive inhibitor controls (CK-312 and CK-689) and DMSO alone served as 
Infected host cells were fixed 30 minutes post infection with 4% paraformaldehyde for 
15 minutes, washed in PBS and blocked with 10% fetal bovine serum. The cells were 
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not permeabilized. Extracellular EBs were labeled for 1 hour with antibodies specific for 
chlamydial momp (L2). After four washes in PBS, secondary antibody conjugated to 
Alexa 488 (green) was added for 1 hour. Coverslips were rinsed and mounted in 
ProLong Gold antifade reagent (Invitrogen).  Cells were examined with a Zeiss Axio 
Observer A1 microscope equipped with phase contrast and epifluorescence optics. 
Images were obtained using an AxioCam MRm camera controlled by AxioVision 4.8.2 
and further processed using Adobe Photoshop CS2. The percentage of internalized 
bacteria was taken as the total EBs (red)−extracellular EBs (green)/total EBs (red)×100. 
Protein samples collected from drug treated host cells identical to those described 
above were infected with C. trachomatis L2 at an MOI of 1000 and were examined by 
Western blot analysis. 
3.2.2. SDS-PAGE and Western Blotting 
Proteins were separated on SDS-10% polyacrylamide gels and stained with 
coomassie R-
immobilization membrane (Schleicher & Schuell, Keene, NH). Immunoblotting employed 
peroxidase conjugated secondary antibodies (Chemicon International, Temecula, CA) 
and Supersignal West Pico chemiluminescent substrate (Pierce, Rockford, IL). The anti-
phosphotyrosine 4G10 monoclonal antibody was purchased from Upstate (Millipore). 
Polyclonal rabbit antibodies directed towards C. trachomatis L2 LGV 434 Tarp was 
developed at Rocky Mountain Laboratories as previously described [243] 
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3.3.3 Cloning, Protein Expression and Purification 
An in frame glutathione-S-transferase (GST) and polyhistidine C. trachomatis L2 
LGV 434  Tarp fusion protein was generated by PCR amplifying the corresponding 
coding regions from C. trachomatis genomic DNA (QIAGEN genomic purification kit, 
Valencia CA) using custom synthesized oligonucleotide primers (Integrated DNA 
Technologies, Coralville, IA) engineered with SalI, SacI or NotI linkers. PCR products 
were purified (QIAGEN), digested with restriction enzymes (New England Biolabs, 
Beverly, MA) and subcloned into linearized pGEX-6P-1 to generate translational fusions 
with GST at the N-terminus and polyhistidine at the C-terminus. The PCR fragments 
described above harboring tarP were also cloned into pEGFP-C3 (BD Biosciences 
Clontech) to allow for the ectopic expression of eGFP-Tarp in HeLa cells. 
pGEX-6P-1 plasmids were transformed into BL21 strain of E. coli (Novagen, 
Madison WI). Protein expression and purification were performed according to the 
procedures outlined for Ni Sepharose 6 Fast Flow and Glutathione sepharose 4B in the 
Bulk GST Purification Module (GE health sciences, Piscataway, NY). 
3.3.4 Actin Polymerization Assay 
The rate of actin polymerization in the presence of Tarp and the Arp2/3 complex 
was monitored according to the methods outlined in the Actin Polymerization Biochem 
Kit BK003 (Cytoskeleton, Denver CO). Briefly, monomeric pyrene labeled actin was 
prepared by diluting 500 ng of lyophilized pyrene actin into 5 mls of 5 mM Tris (pH 8.0), 
0.2 mM CaCl2, and 0.2 mM ATP (G-buffer) and incubating for 1 hour at room 
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temperature followed by an additional hour of incubation at 4oC. Monomeric pyrene 
actin was obtained by collecting the supernatant following a 2 hour, 100,000 rcf, 4oC 
spin in a Beckman Optima TLX Ultracentrifuge using a TLA 100.3 rotor (Beckman 
Coulter Inc., Fullerton, CA). Approximately 40 μg of pyrene labeled actin was gently 
mixed with 2-5 ng of test proteins in a volume of 500 μl for 5 minutes prior to the 
addition of 1/20th volume of polymerization buffer (500 mM KCl, 20mM MgCl2, and 
10mM ATP). The reaction was monitored over one hour with an LS 55 Luminescence 
spectrophotometer equipped with a biokinetics accessory and directed by FL WinLab 
software version 4.0 (Perkin Elmer, Beaconsfield, BUCKS, UK) with 2.5 nm bandwidth 
at 365 nm excitation wavelength and 2.5 nm bandwidth at 407 nm emission wavelength. 
3.3.5 Scanning Electron Microscopy 
Actin filaments were added to an SEM type 3 mount and sputter coated with 8-
10nm chromium. Coated filaments were examined in a Hitachi S5200 scanning electron 
microscope at 30 kV accelerating voltage. 
3.3.6 Transfection of Hela Cells and Indirect Immunofluorescence Microscopy 
HeLa cells (2 X 105 ) were seeded in 6 well plates with coverslips and grown for 
24 hours in DMEM containing 10% FBS. Cells were then transfected with transfection 
mixture containing 8 μl of Fugene HD (promega) and 2.5 mg of respective plasmid. 
Following 24 hours, cells were fixed by adding 4 % paraformaldehyde and incubating at 
40 C for 15 minutes. Cells were then treated with ice cold 0.4 % Triton-X for 10 minutes, 
followed by blocking with 5% BSA for 45 minutes.  To visualize tyrosine phosphorylated 
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protein, cells were first incubated with anti-phosphotyrosine primary antibody (upstate) 
at 1:1000 dilutions in 0.5 % BSA at RT for 45 minutes followed by incubation with anti-
mouse secondary antibody conjugated to Alexa 350 (invitrogen). To simultaneously 
visualize actin, phalloidin conjugated to Alexa 568 (invitrogen) was added to the above 
mixture containing secondary antibodies. To stain for Arp2/3 complex, cells were first 
incubated with anti-Arp3 primary antibody (upstate) at 1:100 dilutions in 0.5 % BSA at 
RT for 45 minutes followed by incubation with anti- rabbit secondary antibody 
conjugated to Alexa 594 (invitrogen). Coverslips were rinsed and mounted in Prolong 
Gold antifade reagent (invitrogen). Cells were examined with a Zeiss Axio Observer A1 
microscope equipped with phase contrast and epifluorescence optics. Images were 
obtained using an AxioCam MRm camera controlled by AxioVision 4.8.2 and further 
processed using Adobe Photoshop CS2. 
3.3 Results 
3.3.1 Arp2/3 Complex is Essential for Entry of C. Trachomatis 
The role of Arp2/3 complex in chlamydial entry was previously confirmed using 
RNA interference and dominant-negative overexpression techniques. In order to test the 
effects of the new pharmacological inhibitors of Arp2/3 complex, CK-666 and CK-869, 
on entry of C. trachomatis, we did an invasion assay using HeLa cell lines that were 
pre-incubated with either media alone or media containing DMSO, Arp2/3 inhibitors 
(CK-666 and CK-869), control inhibitors (CK-312 and CK-689), or Jasplakinolide (Jaz), 
an actin filament stabilizer. Entry of C. trachomatis  was inhibited in HeLa cells that were 
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pre-incubated with Arp2/3 complex inhibitors (CK-666 and CK-869) as compared to 
HeLa cells that were either untreated or treated with DMSO or control inhibitors (CK-312 
and CK-689). These differences are statistically significant. Moreover, treatment of 
HeLa cells with Jasplakinolide (Jaz), a compound that stabilizes filamentous actin, also 
resulted in decreased entry (Fig 16A). To test whether pharmacological inhibition of 
Arp2/3 complex altered the delivery of Tarp into the host cytoplasm, we infected 
pharmacologically pretreated HeLa cells (as mentioned above for invasion) with EBs for 
30 minutes and prepared the samples for western blot analysis. The samples were run 
on SDS-PAGE gel and a western blot analysis with phosphotyrosine Ab was done to 
detect translocated Tarp. The results indicate that the delivery of Tarp is not affected by 
treating the HeLa cells with either Arp2/3 complex inhibitors or Jaz (Fig 16B). Overall, 
the above result confirms the ability of CK-666, CK-869 and Jaz to inhibit entry of C. 
trachomatis, and also that such observed effects were not due to inhibition of effector 
delivery. 
3.3.2 Tarp Cooperates, but does not directly activate Arp2/3 Complex to 
Polymerize Actin 
Nucleating activity of Tarp differs from Arp2/3 complex in that Tarp generates 
linear actin filaments, whereas Arp2/3 uses linear filaments to form the branching 
pattern of filamentous actin [64, 400]. To test if these two nucleators cooperate to alter 
the kinetics of F-actin, an in vitro actin polymerization assay was done using 
fluorescently labeled actin. Mixtures containing actin alone or actin in combination with 
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Tarp, activated Arp2/3(Arp2/3 + VCA), or both were allowed to polymerize following the 
addition of polymerization buffer. The increase in fluorescence intensity was measured 
over time and graphed as a readout of the rate of actin polymerization (Fig 17B). The 
sample containing both nucleators showed an increased rate of actin polymerization as 
compared to other samples containing either a single nucleator or actin alone. 
Moreover, the lag phase that represents initial actin nucleation was not observed in 
samples containing Tarp. This suggests that Tarp and Arp2/3 complex cooperate to 
promote actin polymerization. To test whether phosphorylation alters the ability of Tarp 
to cooperate with Arp2/3 complex, Tarp was phosphorylated using commercially purified 
Fyn kinase. Phosphorylation of Tarp was confirmed by western blot analysis using 
phosphotyrosine antibody (Fig.17C) and actin polymerization kinetics of phosphorylated 
Tarp were assessed in combination with activated Arp2/3 complex. Phosphorylated 
Tarp retained the ability to cooperate with activated Arp2/3 complex (Fig. 17D). To test 
whether Tarp or phosphorylated Tarp can directly activate Arp2/3 complex, an actin 
polymerization assay was performed using Tarp or phosphorylated Tarp in presence of 
inactive Arp2/3 complex (Arp2/3-VCA). No alteration in the kinetics of actin 
polymerization was observed in samples containing both Tarp (phosphorylated or not) 
and inactive Arp2/3 complex as compared to Tarp or phosphorylated Tarp alone (Fig. 
17B and 17D).  Finally, to visualize the patterns of actin filaments generated by actin 
alone or in presence of either single or double nucleators, an actin polymerization assay 
was run for 10 minutes and actin filaments were then visualized using scanning electron 
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microscopy. Actin filaments in samples containing Tarp and activated Arp2/3 showed 
more branching patterns as compared to samples containing either actin alone or single 
nucleators (Fig. 17E). Overall, this data suggests that Tarp and Arp2/3 complex 
cooperates to promote actin polymerization, but Tarp does not directly activate Arp2/3 
complex. 
3.3.3 Ectopically expressed eGFP-Tarp Co-localize with F-Actin, but not with 
Arp2/3 Complex 
Tarp co-localization with actin has been studied in the past [243]. Full length and 
C-terminal domain of Tarp were found to co-localize with actin aggregates [243]. Later, 
the ABD in the C-terminal domain of Tarp was identified as the site responsible for 
binding actin and causing actin aggregation [64]. Phosphorylated Tarp peptide was 
previously demonstrated to interact with recruitment of SOS and Vav, a guanine 
nucleotide exchange factor (GEF) responsible for Rac GTPase activation [312]. To 
examine whether phosphorylated Tarp can recruit Arp2/3 complex to alter actin 
dynamics in vivo, we constructed mammalian expression plasmids with EGFP-fusions 
of full length Tarp, the N-terminal mutant harboring the phosD and PRD domains (Tarp1-
748), and the C-terminal mutant harboring the PRD and ABD domains (Tarp625-1005)(Fig  
18A). The mutants were specifically engineered to study the individual contribution of 
the actin binding domain and the phosphorylation domain of Tarp in regulating actin 
dynamics. It was previously demonstrated that expression of the phosphorylation 
domain without PRD does not form aggregates and appears to co-localize in the 
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nucleus [306]. Thus, the mutants were designed to retain the PRD domain responsible 
for Tarp aggregation. Following 24 hour transfection in HeLa cells, we fixed and stained 
cells to detect Arp2/3 complex, actin, and also to study the phosphorylation pattern of 
Tarp protein. The full length Tarp formed EGFP aggregates, was phosphorylated, and 
co-localized with actin (Fig 18B and 18C). The mutant with the C-terminal half, 
harboring PRD and ABD, formed EGFP aggregates that were not phosphorylated but 
co-localized with actin (Fig 18B and 18C). Interestingly, the mutant with the N-terminal 
half of Tarp, harboring the phosphorylation domain and PRD, formed intracytoplasmic 
EGFP aggregates that appeared to be phosphorylated but failed to co-localize with actin 
(Fig 18B and 18C). Furthermore, neither the full length nor the mutant Tarp constructs 
were able to recruit Arp2/3 complex (Fig. 18C). 
3.4 Discussion 
 
Invasion of bacteria is a complex and highly regulated process that requires 
coordinated rearrangement of host actin cytoskeleton. In chlamydial entry, such 
cytoskeletal rearrangement requires the activity of the chlamydial and the host actin 
nucleator, Tarp and Arp2/3 complex respectively [307, 312]. Previous studies employed 
RNA interference and dominant negative overexpression of Arp2/3 activators to confirm 
the role of Arp2/3 complex in chlamydial entry. Recently, specific inhibitors of Arp2/3 
complex CD-666 and CD-869 have been described [399]. Since pharmacological 
inhibition is a relatively simple, cheap, and fast technique to use as compared to gene 
manipulation, we decided to test the effects of these inhibitors on entry of chlamydia. 
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CD-666 and CD-869 mediated inhibition of Arp2/3 complex abrogated chlamydial entry 
as compared to their control counter parts in a statistically significant manner. This data 
further confirms the role of the Arp2/3 complex in the entry of chlamydia and that these 
inhibitors can be used as a scientific tool to elucidate chlamydial entry mechanisms in 
future studies. Interestingly, Jasplakinolide, a compound that stabilizes filamentous actin 
and prevents depolymerization, also inhibited chlamydial entry [401]. This suggests that 
chlamydial entry is a product of the coordinated rearrangement of the actin cytoskeleton 
requiring spatially and temporally restricted patterns of actin polymerization and 
depolymerization. Consistently, a chlamydial effector protein CT166 was recently 
identified and implicated in inhibition of Rac GTPases [244].  
Because Tarp and Arp2/3 are both essential for chlamydial entry, it was 
previously hypothesized that these two nucleators may cooperate to cause efficient 
chlamydial uptake. However, the molecular mechanisms of such cooperation between 
Tarp and Arp2/3 complex were not known. One possibility was that the Arp2/3 complex 
activity might be essential in priming the host cells for delivery of effector proteins by 
chlamydia, a mechanism which is recently identified to be essential for effector delivery 
by E. coli [402].  However, Chlamydia retained the ability to deliver Tarp in host cells 
pharmacologically inactivated for the Arp2/3 complex (Fig 16B). This suggests that 
Arp2/3 complex activation plays a critical role in entry mechanism following delivery of 
effector protein Tarp.  
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Previous evidence implicates the distinct patterns of actin filaments generated by 
Tarp and Arp2/3 complex activity. Tarp binds and nucleates actin monomers to form 
linear actin filaments, whereas Arp2/3 complex interacts with pre-existing linear 
filaments and branch it at 700 angles [64, 403]. Thus, it is possible that Tarp activity 
provides linear actin filaments as a substrate for Arp2/3 complex activity, which together 
results in the rapid rearrangement of the actin necessary for efficient chlamydial uptake. 
Indeed, in an in vitro actin polymerization assay when Tarp and activated Arp2/3 
complex were added together, the rate of actin polymerization was increased as 
compared to samples containing solely these individual nucleators. Scanning electron 
microscopy further confirmed these findings as extensive branching patterns were 
observed when Tarp and Arp2/3 were added together. One of the ways in which the 
functions of many proteins are altered is via the addition or removal of the phosphate 
moiety. Since Tarp is phosphorylated inside the host cytoplasm, we were interested in 
studying the effects of phosphorylation on the ability of Tarp to cooperate with Arp2/3 
complex. Tarp proteins phosphorylated with Fyn kinase retained the ability to cooperate 
with Arp2/3 complex. Together, our data provides the first biochemical evidence 
indicating that Tarp and Arp2/3 complex cooperate to increase the rate of actin 
polymerization.  
While Tarp is inherently active, the Arp2/3 complex is highly regulated and 
requires activation by nucleation promoting factors (NPF) like WASP and WAVE [404]. 
Many eukaryotic signaling cascades that are initiated following receptor-ligand 
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interaction converge to regulate the interaction between NPF and Arp2/3 complex. 
Interestingly, some bacterial effector proteins, like Act A in L. monocytogenes and RickA 
in R.coronii, mimic the activity of NPF to cause direct activation of Arp2/3 complex, 
whereas other bacterial effectors in E.coli, Salmonella and Shigella promotes activation 
of Arp2/3 complex by influencing upstream host signaling proteins like Rho family 
GTPases [65, 405-408]. Whether or not Tarp exhibits NPF activity has never been 
tested. Our actin polymerization assay demonstrated that addition of Tarp (either 
phosphorylated or not) and Arp2/3complex in the absence of known NPF produces no 
change in actin polymerization kinetics as compared to Tarp alone. This data clearly 
indicates that Tarp alone is not efficient to activate Arp 2/3 complex. Previous evidences 
also implicate the role of phosphorylated Tarp in the recruitment of Sos1 and Vav2, two 
guanine nucleotide exchange factors, which in turn participate in WAVE2-Arp2/3 
complex recruitment and activation. To examine whether Tarp, via its phosphorylation 
domain, indirectly regulates Arp2/3 activation to alter actin dynamics in vivo, we 
ectopically expressed an EGFP fusion of Tarp harboring the phosphorylation and 
proline rich domains, but missing the actin binding domain, in HeLa cells. Our data 
demonstrates that although EGFP fusion proteins were phosphorylated, they failed to 
co-localize with Arp2/3 complex or actin. Such discrepancy with the previous 
observations could be due to different scientific techniques applied to study function of 
Tarp. Previous observations were based on the ectopic expression of a single tyrosine 
rich repeat of the phosphorylation domain in Tarp, whereas we had engineered Tarp 
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constructs so that they retain the entire phosphorylation domain as it is found in the full 
length Tarp protein. Moreover, we also did not observe the recruitment of Arp2/3 
complex in HeLa cells that expressed full length or the C-terminal domain of Tarp 
protein, while these constructs retained the capacity to recruit actin. Together this data 
suggests that Tarps ability to alter actin dynamics is solely a function of the C-terminal 
domain of Tarp and that phosphorylated Tarp is not responsible for Arp2/3 activation or 
actin remodeling.  
Collectively, we have demonstrated that Arp2/3 complex inhibitors CK-666 and 
CK-869 can be used as pharmacological tools in studying the mechanism of chlamydial 
entry. Importantly, we demonstrated for the first time that Tarp and Arp2/3 complex 
cooperate to increase the rate of actin polymerization. Furthermore, Tarp plays no role 
in the activation of Arp2/3 complex. While the signaling event responsible for activation 
of Arp2/3 complex is still a mystery, recent evidences implicate the role of fibroblast 
growth factor receptors (FGFR) in chlamydial entry [238]. FGFR mediated signaling can 
activate Arp2/3 complex via Ras GTPase activating like protein 1 (IQGAP-1) in other 
systems [409]. The role of IQGAP-1 in chlamydial entry is not yet studied. Whether 
Arp2/3 complex activation is the result of FGFR mediated signaling and/or some other 
host signaling event(s) remains to be determined. 
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3.5 Figures 
 
 
 
 
 
Figure 16 Arp2/3 complex is required for entry of Chlamydia trachomatis. 
 Graphical representation of C. trachomatis EB invasion assay in HeLa cells 
pharmacologically treated with Arp2/3 complex inhibitors CK-666 and CK-869.  HeLa 
cells were treated for one and a half hours at 370C with 200 uM concentration of either 
Arp2/3 complex inhibitors (CK-666 and CK-869), control inhibitor (CK-312 and CK-689) 
or Jasplakinolide (Jaz, an actin stabilizer). Invasion assay was performed using CMPTX 
labeled florescent EBs (Red).  After allowing 30 minutes of invasion, extracellular EBs 
were counterstained with antibodies targeting MOMP (L2) and anti-mouse antibody 
conjugated to Alexa 488 (Green). EB entry was determined as percent invasion. Media 
alone or DMSO served as an additional negative control. Graph represents cumulative 
result from three independent experiments (B) Delivery of Tarp into host cells is not 
affected by Arp2/3 complex inhibitor. Protein samples collected from drug treated host 
cells identical to those described above were infected with C. trachomatis L2 at an MOI 
of 1000 and were examined by Western blot analysis. Phosphotyrosine antibody was 
used to detect intracytoplasmic phosphorylated Tarp. Tarp antibody was used to detect 
total Tarp protein and Actin blot served as loading control. 
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Figure 17 Tarp co-operates, but does not activate Arp2/3 complex to polymerize 
actin. 
 (A) Dual Tag (N-terminal GST and C-terminal poly histidine) recombinant full length 
Tarp protein (Tarp) was double purified using gluthathione sepharose and nickel beads 
and subsequently resolved on 10% SDS page gel to analyze for purity and quantity by 
staining with coomassie blue. The same quantity of protein represented in the figure 
was used for subsequent analysis. (B) Actin polymerization assay was performed by 
mixing 1 mM of fluorescently labeled pyerene conjugated actin with Tarp, activated 
Arp2/3 complex (Arp2/3 + VCA), Tarp and activated Arp2/3(Tarp+ Arp2/3+VCA), or 
Tarp and Arp2/3 (Tarp+ Arp2/3). The rate of actin polymerization was measured by the 
increase in fluorescence intensity (Intensity a. u.) over 1hr following addition of 
polymerization buffer at 300 sec. Actin alone or addition of GST, VCA, or Arp2/3 served 
as controls. (C) Tarp was phosphorylated by incubating Tarp with purified Fyn kinase 
and ATP at 370C for 5 mins. The phosphorylation of Tarp was confirmed by performing 
SDS-PAGE and western blot analysis using phosphotyrosine specific and total Tarp 
antibodies. (D) Actin polymerization assay was performed exactly as described in (B) 
except using phosphorylated Tarp (TarpPO4) instead of Tarp. 
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Figure 18 Ectopically expressed egfp-Tarp co-localizes with actin, but not with 
Arp2/3 complex. 
 (A) Schematics of EGFP-fusion of full length (Tarp), actin binding domain deletion 
mutant (Tarp(1-747)) and phosphorylation domain deletion mutant (Tarp(624-1005)) of Tarp 
protein used for immunofluorescence Assay.  The domains of Tarp are color coded as 
follows: phosphorylation domain (green box), proline rich domain (blue box) and actin 
binding domain (red box). Δ represents amino acid deletion and number represents 
amino acid position in Tarp polypeptide. (B) HeLa cells were transfected with EGFP-
fusions of full length Tarp, Tarp(1-747), and Tarp(624-1005) for 24 hours, followed by fixation 
and staining with Alexa-568 conjugated phalloidin (Red) and phosphotyrosine specific 
primary and corresponding Alexa-350 conjugated secondary antibodies (Blue). (C) 
Similar transfection as described in B was performed and samples were stained with 
primary Arp 3 and corresponding Alexa-568 conjugated secondary antibodies. Images 
were obtained using an AxioCam MRm camera controlled by AxioVision 4.8.2 and 
further processed using Adobe Photoshop CS2. 
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CHAPTER FOUR: CHLAMYDIA TRACHOMATIS TARP HARBORS 
DISTINCT G AND F ACTIN BINDING DOMAINS WHICH BUNDLE ACTIN 
FILAMENTS. 
 
4.1 Introduction 
 
The obligate intracellular bacterium, Chlamydia trachomatis, is the most 
frequently reported sexually transmitted bacterial disease in the United States with over 
one million cases reported to the Centers for Disease Control annually. Worldwide, 
ocular infection with C. trachomatis (trachoma) is the leading cause of preventable 
blindness and is the subject of a global initiative led by the World Health Organization to 
eradicate Trachoma by 2020[410]. 
Species of Chlamydia utilize a unique developmental cycle in which bacteria 
transition from the infectious spore-like elementary body (EB) to the metabolically active 
reticulate body (RB) within the protective confines of a membrane bound 
parasitophorous vacuole termed the inclusion [223]. The invasive EB is formed in the 
mid to late stages of the intracellular development cycle as the RBs differentiate back to 
EBs and are packed with metabolites and proteins designed to facilitate extracellular 
survival and reinfections. [224, 225]Additional infectious cycles arise from EBs that are 
released and disseminate from infected tissues [226]. 
C. trachomatis invasion is induced by cytoskeletal rearrangements initiated upon 
microbe contact with the host cell surface [292]. Alterations of the host cytoskeleton are 
required for bacterial uptake as drugs such as Cytochalasin D which disrupt the 
cytoskeleton prevent C. trachomatis infections [292]. A number of intracellular 
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microorganisms harbor proteins that directly alter actin dynamics which favor pathogen 
survival and propagation [411]. These virulence factors can drive the formation of actin 
filaments, and actin bundles or can lead to the disassembly of actin filaments. 
Cytoskeletal rearrangements initiated upon EB contact with the host cell surface may in 
part be triggered by the translocation of type III secreted effectors [242, 243]. One of the 
effector proteins called translocated actin recruiting protein (Tarp) is able to increase 
the rate of actin filament formation by directly nucleating actin [64]. In addition, Tarp and 
the host cell Arp2/3 actin nucleating complex cooperate to increase the rate of actin 
filament formation and both host and bacterial derived actin nucleators are implicated in 
C. trachomatis invasion [296, 307, 412]. 
Tarp contains a C- terminal  actin binding and oligomerization domain required 
for actin nucleation  and a N-terminal phosphorylation domain implicated in host cell 
signaling via association with host derived proteins such as phosphoinositide 3-kinase 
(PI3K) and Src homology 2 (SH2) domain containing transforming protein 1 (SHC-1) 
[64, 306, 312, 398]. Phosphorylated Tarp peptides have also been shown to 
immunoprecipitate a complex of proteins containing Sos1, Vav2, two Rac guanine 
nucleotide exchange factors thought to participate in WAVE2 and Arp2/3 complex 
recruitment [312]. Co-localization studies of ectopically expressed eGFP-Tarp indicate 
that actin filament recruitment is restricted to the C-terminal half of the effector and is 
presumably associated with Tarp via the previously identified actin binding alpha helix 
required for actin nucleation in vitro [306, 412]. In this work we examined the effect of 
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domain specific mutations on actin filament co-localization with eGFP-Tarp. Herein we 
describe that C. trachomatis L2 Tarp harbors two distinct F-actin binding sites that allow 
the Tarp effector to bundle actin filaments. Furthermore, Tarp mediated actin bundling 
did not require actin nucleation as the ability to bundle actin filaments was observed in 
mutant Tarp proteins deficient in actin nucleation. These findings attribute a novel 
activity to the critical Tarp protein and shed molecular insight into the complex 
cytoskeletal rearrangements required for C. trachomatis entry into host cells. 
4.2 Material and Methods 
 
4.2.1 Cloning and Protein Expression 
In-frame amino-terminal GST and carboxyl-terminal polyhistidine fusion proteins 
for full-length wild-type Tarp was generated by PCR by amplifying the corresponding 
coding regions from Chlamydia trachomatis servovar L2 LGV 434 genomic DNA 
(Qiagen genomic purification kit, Valencia, CA) as previously described using custom 
synthesized oligonucleotide primers (Integrated DNA Technologies, Coralville, IA) 
engineered with SalI, SacI or NotI linkers. PCR products were purified (Qiagen), 
digested with restriction enzymes (New England BioLabs, Beverly, MA), and subcloned 
into linearized pGEX-6P-1 to generate translational fusions with GST and polyhistidine. 
Tarp domain deletion mutants: phosphorylation domain deletion (ΔphoD =Δ D125-
Y424), proline rich domain deletion (ΔPRD = ΔS625-N650), actin binding domain 
deletion (ΔABD = Δ748-758), F-actin binding domain deletion 1 (ΔFAB1 = ΔL871-L882) 
and F-actin binding domain deletion 2 (ΔFAB2 = ΔN942-G967) were generated by 
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inverse PCR by amplifying the pGEX-6P-1 plasmids encoding the wild type Tarp fusion 
protein. Multiple domain deletions in a single tarP gene (for example: ΔABD, ΔFAB1 & 
ΔFAB2) were generated sequentially by inverse PCR or by ligating individual deletion 
mutants together. The Tarp mutants described above were also cloned into pEGFP-C3 
(BD Biosciences Clontech) to allow for ectopic expression of eGFP-Tarp in HeLa cells.  
All pGEX-6P-1 plasmids were transformed into the BL21 strain of Escherichia coli 
(Novagen, Madison, WI). Protein expression and purification were performed according 
to the procedures outlined for the Ni Sepharose 6 Fast Flow and Glutathione Sepharose 
4B in the Bulk GST Purification Module (GE health sciences, Piscataway, NY). 
4.2.2 GST Fusion Pull-Down Experiment 
HeLa 229 cells were suspended in 100mM KCl, 10mM HEPES (pH 7.7), 2mM 
MgCl2 and 2mM ATP (buffer A) and disrupted by sonication delivered in four 
consecutive bursts of 20 second intervals on setting  #4 (ultrasonic sonicator processor 
XL equipped with microtip: Misonix Incorporated, Farmingdale, NY). Insoluble material 
was removed by centrifugation (12,000 rcf, 25 min., 4oC). Glutathione-sepharose beads 
were incubated with 10mg of GST fusion proteins or GST for 1 hour at 4oC in PBS. (GE 
health sciences). GST-fusion protein coated beads were washed twice with PBS and 
once with buffer A prior to the addition of approximately 100mg of HeLa extract. 
Extracts and beads were incubated together for 2 hours at 4oC, washed three times with 
fresh buffer A and bound proteins were eluted using sample buffer. 
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4.2.3 SDS-PAGE and Immunoblotting 
Proteins were separated on SDS-10% polyacrylamide gels and transferred to 
Schuell, Keene, NH). Immunoblotting employed peroxidase conjugated secondary 
antibodies (Chemicon International, Temecula, CA) and Supersignal West Pico 
chemiluminescent substrate (Pierce, Rockford, IL). The anti-actin C4 monoclonal 
antibody was purchased from Chemicon International. The anti-phosphotyrosine 4G10 
monoclonal antibody was purchased from Upstate (Millipore). Polyclonal rabbit 
antibodies directed towards Chlamydia trachomatis L2 LGV 434 Tarp (CT456) was 
developed at Rocky Mountain Laboratories as previously described [243]. Peptide 
antibodies directed toward the Tarp actin binding domain and proline rich domain were 
generated and purified by Sigma Genosys (Spring, TX) as previously described [307]. 
4.2.4 Transfection of Hela Cells and Indirect Immunofluorescence Microscopy 
Hela cells (2 X 105 ) were seeded in 6 well plates with coverslips and grown for 
24 hours in DMEM containing 10% FBS. Cells were then transfected with transfection 
mix
Following 24 hours, cells were fixed by adding 4 % paraformaldehyde and incubating at 
40 C for 15 minutes. Cells were then treated with ice cold 0.4 % Triton-X for 10 minutes, 
followed by blocking with 5% BSA for 45 minutes.  To visualize tyrosine phosphorylated 
protein, cells were first incubated with anti-phospho tyrosine primary antibody (upstate) 
at 1:1000 dilutions in 0.5 % BSA at RT for 45 minutes followed by incubation with anti-
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mouse secondary antibody conjugated to Alexa 350 (invitrogen). To simultaneously 
visualize actin, phalloidin conjugated to Alexa 568 (invitrogen) was added to the above 
mixture containing secondary antibodies. To stain for Arp2/3 complex, cells were first 
incubated with anti-Arp3 primary antibody (upstate) at 1:100 dilutions in 0.5 % BSA at 
RT for 45 minutes followed by incubation with anti- rabbit secondary antibody 
conjugated to Alexa 594 (invitrogen). Coverslips were rinsed and mounted in Prolong 
Gold antifade reagent (invitrogen). Cells were examined with a Zeiss Axio Observer A1 
microscope equipped with phase contrast and epifluorescence optics. Images were 
obtained using an AxioCam MRm camera controlled by AxioVision 4.8.2 and further 
processed using Adobe Photoshop CS2. 
4.2.5 F-Actin Binding and Bundling 
Briefly, 5 μg of GST fusion proteins or control proteins (GST and a-actinin) were 
added to 40 μg of filamentous actin [F actin; generated by adding 1/10th volume of 
polymerization buffer to G actin and incubating at room temperature (RT) for 1 h] and 
allowed to incubate at RT for 30 min. F actin and bound proteins were separated by 
differential sedimentation at 100,000 ´ g for 2 h at RT in a Beckman Optima TLX 
Ultracentrifuge using a TLA 55 rotor (Beckman Coulter, Fullerton, CA). Proteins 
associated with the F actin pellets were compared to unbound proteins that remained in 
the supernatant by resolving proteins on 10% SDS-polyacrylamide gels followed by 
Coomassie staining. 
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4.2.6 G Actin Binding Assay 
Monomeric actin was prepared by diluting 100 mg of lyophilized rabbit muscle 
actin (Cytoskeleton, Denver, CO) into 2 ml of 5 mM Tris (pH 8.0)/0.2 mM CaCl2/0.2 mM 
ATP/0.1% Tween 20 (G buffer with tween) and incubating for 1 h at RT. Monomeric 
actin was obtained by collecting the supernatant after a 2-h 100,000 ´g 4°C spin in a 
Beckman Optima TLX Ultracentrifuge using a TLA 55 rotor (Beckman Coulter). 
Monomeric actin was incubated with »5 mg of GST fusion proteins immobilized to 
glutathione Sepharose beads (prepared as described above). After gentle mixing for 2 h 
at 4°C, beads were washed three times with fresh G buffer, and bound proteins were 
eluted using sample buffer. 
4.2.7 Actin Polymerization Assay 
Briefly, monomeric pyrene labeled actin was prepared by diluting 100 mg of 
lyophilized pyrene actin (Cytoskeleton) into 2 ml of 5 mM Tris (pH 8.0)/0.2 mM 
CaCl2/0.2 mM ATP (G buffer) and incubating for 1 h at RT followed by 1 additional hour 
of incubation at 4°C. Monomeric pyrene actin was obtained by collecting the 
supernatant after a 2-h 100,000 ´g 4°C spin in a Beckman Optima TLX Ultracentrifuge 
using a TLA 55 rotor (Beckman Coulter). Approximately 20 mg of pyrene-labeled actin 
was gently mixed with 5 mg of GST fusion proteins in a volume of 500 ml for 10 min 
before the addition of 1/20th volume of polymerization buffer (500 mM KCl/20 mM 
MgCl2/10 mM ATP). The reaction was monitored over 1 hr with an LS 50B 
Luminescence spectrophotometer directed by FL WinLab software version 4.0 (Perkin-
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Elmer, Beaconsfield, Bucks, UK) with 2.5-nm bandwidth at 365-nm excitation 
wavelength and 2.5-nm bandwidth at 407-nm emission wavelength. 
4.3 Results 
4.3.1 Mutant Tarp Proteins Exhibit Unique Actin Binding and Polymerization 
Kinetics. 
The actin nucleating activity of Tarp results from distinct actin binding and proline 
rich oligomerization domains in vitro [64] and potentially from a signaling cascade 
involving the recruitment and activation of Vav2, Sos1, Eps8, Abi1, Rac1 and WAVE2  
in vivo [296, 299, 312]. C. trachomatis L2 Tarp is a large 1005 amino acid protein and 
studies to date have primarily focused on recombinant Tarp truncation mutants or Tarp 
peptides to identify the domains of the protein responsible for Tarp mediated actin 
polymerization [64, 243, 307]. To confirm that the previously identified domains were 
sufficient for actin binding and actin nucleation in the entire Tarp effector we have 
generated a series of GST and eGFP recombinant full length L2 Tarp deletion mutants 
that are missing the phosphorylation, the actin binding and/or the proline rich 
oligomerization domain to examine the contribution that each domain has on actin 
kinetics biochemically and in HeLa cells (Fig. 19A). Wild type Tarp and deletion mutant 
Tarp proteins with dual N-terminal GST and C-terminal poly histidine affinity tags were 
purified and employed in actin binding and actin polymerization assays (Fig. 19B, 19C). 
All full length Tarp mutants were able to associate with host cell actin in a GST– 
pulldown assay except for the ΔABD Tarp mutant harboring an 11 amino acid deletion 
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(aa 748-758) of the previously characterized actin binding domain (Fig. 19B) [64]. The 
purified Tarp proteins also demonstrated distinct actin polymerization kinetics as 
observed in in vitro pyrene actin polymerization assays (Fig. 19C). An increase in the 
rate of actin polymerization was observed in wild type Tarp and the Tarp effector 
harboring a deletion in the phosphorylation domain compared to actin alone controls 
which is in agreement with reports localizing the Tarp actin nucleating activity to the C-
terminal half of the protein [64, 243, 307, 412]. Consistent with previous studies, 
removal of a short proline rich domain of 25 amino acids implicated in oligomerization 
activity was also required for actin nucleation (Fig. 19C) [64]. Surprisingly, when actin 
filament co-localization with eGFP-Tarps was examined in HeLa cells with alexa-
conjugated phalloidin, Tarp mutants lacking the actin binding domain (Tarp ΔABD) 
retained the ability to co-localize with actin filaments (Fig. 19D). A Tarp eGFP fusion 
lacking the amino acids 748-1005 (Tarp1-747) did not co-localize with phalloidin and 
served as a negative control (Fig.19D).  eGFP-Tarp harboring mutations in both the 
phosphorylation and actin binding domain simultaneously also were able to co-localize 
with actin filaments (data not shown). These data suggest that Tarp may harbor an as 
yet uncharacterized F-actin binding domain(s) distinct from the previously characterized 
G-actin binding domain that is essential for actin nucleation. 
4.3.2 C. Trachomatis L2 Tarp Harbors A Distinct F-Actin Binding Domain. 
Tarp orthologs contain between one and four actin binding domains according to 
GST-pull down assays performed with HeLa extracts [307]. Previous reports have 
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indicated that C. trachomatis L2 Tarp harbors one actin binding domain which is 
consistent with the data presented in figure 19[64, 307]. Deletion of 11 amino acids 
contained within the L2 Tarp actin binding domain was sufficient to prevent actin binding 
in the GST-pull down assay compared to the wild type control. Interestingly a second 
putative actin binding domain which is similar in sequence to the characterized L2 Tarp 
actin binding domain was previously identified bioinformatically but was unable to 
associate with host cell actin in a GST-pull down assay [307]. Our contradictory findings 
suggested that Tarp may harbor protein domains which differentiate between 
monomeric (globular) actin found predominately in the HeLa generated protein lysates 
and filamentous actin detected by fluorescent phalloidin in the transfected host cells. In 
order to examine whether the second actin binding-like domain found in C. trachomatis 
L2 Tarp sequence was able to differentially associate with globular versus filamentous 
actin, GST-Tarp fusions to this domain was tested for the ability to associate with actin 
generated from HeLa lysates in a GST-pulldown and an F-actin co-sedimentation 
binding assay (Fig. 20). Similar to our previous findings, the 100 amino acid peptide 
harboring the original actin binding domain was able to associate with actin generated 
from a HeLa lysate, however, the additional putative sequence did not associate with 
actin generated from the same lysate (Fig. 20A) [64, 307]. Interestingly the two domains 
did co-sediment with filamentous actin indicating the second domain preferentially 
associates with filamentous actin while the original actin binding domain is able to 
associate with both monomeric and filamentous actin as previously described (Fig.20B) 
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[64]. Since the second actin binding site prefers F-actin we have called this site the F-
actin binding site (FAB1) to differentiate it from the originally characterized actin binding 
domain (ABD). 
4.3.3 Tarp Harbors Multiple F-Actin Binding Sites 
Identification of an alternate F-actin binding site in Tarp was examined with a 
GST fusion to 115 amino acids of Tarp representing the region of the protein adjacent to 
the previously characterized actin binding domain. This domain contains a 13 amino 
acid peptide with similarity to the described ABD which is also predicted to form the 
alpha helix secondary structure required for actin binding. Further secondary structure 
predictions of the c-terminal domain of Tarp revealed an additional alpha helix located 
between amino acid 942-967 although this peptide does not share sequence similarity 
with the former two sites (data not shown). In order to determine if the ABD and two 
additional alpha helical domains were responsible for co-localization with filamentous 
actin in tissue culture cells, an eGFP fusion to Tarp harboring all three alpha helical 
deletions was tested for actin co-localization (Fig. 21). An eGFP-Tarp fusion harboring 
the single ABD and an eGFP-Tarp fusion harboring a double mutant ABD and the first 
putative F-actin binding site were also tested. As previously observed the ΔABD mutant 
was able to co-localize with actin filaments as was the double mutant harboring both the 
ΔABD and a deletion in the first alpha helix (ΔFAB1). Interestingly when all three sites 
were removed from Tarp, F-actin co-localization was not observed suggesting that all 
three sites may serve as F-actin binding domains (Fig. 21C). We have termed the last 
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alpha helix the “F-actin binding domain 2” (FAB2). To confirm the eGFP co-localization 
results, GST fusions of Tarp harboring deletions in ABD, FAB1 and FAB2 were used to 
biochemically examine co-sedimentation of actin filaments with recombinant proteins.  
Consistent with the eGFP results, Tarp proteins (with the GST removed) demonstrated 
a reduction in their ability to co-sediment with preformed actin filaments as each domain 
of the protein was removed. This could be observed as both a reduction in the quantity 
of Tarp mutants fractioned to the pellet, and an increase in the Tarp proteins retained in 
the supernatant (Fig. 21B). Tarp proteins lacking all three actin binding sites showed 
the least F-actin binding (Fig. 21B). 
4.3.4 Tarp Bundles Actin Filaments 
Tarp has previously been shown to function as an actin nucleator [64]. The actin 
nucleating activity was localized to a 200 amino acid region of the Tarp protein 
sequence that was found to contain a proline rich region responsible for protein 
oligomerization and a solitary actin binding domain [64]. This actin binding domain was 
able to associate with monomeric and filamentous actin [64]. In light of the identification 
of two additional F-actin binding domains we sought to examine whether Tarp was 
capable of bundling actin filaments. Actin bundles sediment at a faster rate compared to 
actin filaments and monomeric actin. Therefore, proteins capable of bundling actin 
filaments will appear in the pellet upon a low speed centrifugation. Interestingly, Tarp 
was capable of bundling actin filaments (Fig. 20A) and actin bundling was not 
dependent on Tarp mediated actin nucleation as the Tarp ΔPRD mutant which fails to 
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nucleate actin in vitro (Fig. 19) retained actin bundling activity (Fig. 22B). The Tarp 
triple mutant lacking the ABD, FAB1 and FAB2 alpha helices was unable to bundle actin 
filaments which is consistent with both the eGFP co-localization and F-actin co-
sedimentation results (Fig. 22A). 
4.4 Discussion 
 
The Tarp effector is a multifunctional protein which primes the host cell for 
bacterial entry and residence. We now demonstrate that Tarp harbors distinct G-actin 
binding and nucleating as well as F-actin binding and bundling activity.  All three 
domains are similar in that they mediate a direct link to the host cytoskeleton yet 
biochemically they are distinct sites that differentially associate with globular or 
filamentous actin. 
EB attachment to the surface of an epithelial cell ultimately results in the 
formation of an actin rich pedestal at the site of contact and is associated with bacterium 
invasion [292]. Actin filament destabilizing drugs such as cytochalasin D inhibit the 
formation of these projections and subsequent uptake of C. trachomatis [292]. The 
arrangement of the actin filaments within the pedestal is unknown, but presumably the 
actin filaments form polarized actin bundles (actin filaments sharing the same 
orientation with relation to their barbed (+) and pointed ends (-)) similar to those 
characterized in microvilli and filopodia [413]. Actin bundling proteins such as fascin-1 
co-localize with filopodia on the leading edge of the growth cone of developing nerve 
cells and are implicated in the formation of actin bundles [414]. Similarly, Tarp may 
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serve a role in the formation of actin bundles located directly beneath the invading 
microbe.  C. trachomatis entry into host cells in vitro is temperature dependent and 
involves the recruitment of actin to the site of EB attachment [292].  Once internalized, 
the recruited actin quickly disseminates. The molecular details of actin disassembly are 
not well defined, and it is possible that actin depolymerization itself drives EB entry. 
Actin filament stabilizing drugs such as Jasplakinolide (Jas) inhibit EB entry [299, 412], 
although the effects of Jas on actin filaments in vivo is controversial as changes in cell 
morphology that are consistent with a reduction in filamentous actin are observed in 
some Jas treated cells[401]. 
Similar to Tarp, the Salmonella enterica serovar Typhimurium SipC effector is 
able to nucleate actin and bundle actin filaments [308, 415]. Recently, mutant bacteria 
lacking the C-terminal region of SipC responsible for F-actin binding and bundling were 
found to be less invasive compared to wild type Salmonella suggesting that the bundling 
activity of SipC plays a role in pathogen entry into HeLa cells [8].  Whether Tarp‟s ability 
to bundle actin filaments also contributes to pathogen entry is unknown but worthy of 
investigation as new molecular tools continue to be developed to examine the genetic 
requirements of C. trachomatis pathogenicity [416, 417]. 
Actin bundles are tightly controlled by a variety of actin binding proteins (ABPs) 
which drive specific cytoskeletal processes and result in actin assemblies of defined 
thickness, length and organization. The architecture of Tarp mediated actin bundles has 
not been investigated and it will be intriguing to compare them to bundles formed in the 
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presence of other bacterial effectors such as SipC. It is possible that evolutionally 
divergent bacterial species employing unique effector proteins can create similar actin 
bundles for the same purpose.  Whether actin bundles actually contribute to microvilli 
morphogenesis is controversial as a recent study has demonstrated that mice deficient 
in three actin bundling proteins, villin, espin and plastin-1still developed microvilli albeit 
with slightly altered actin architecture. 
Following translocation into host cytoplasm, Tarp gets phosphorylated at its n-
terminal phosphorylation domain by variety of host cell kinases including Src, Abl and 
Syk[306, 309]. In vitro analysis has revealed the ability of phosphorylated Tarp to 
interact with SH2 domain containing proteins including PI3-Kinase and SHC1 adaptor 
protein [398]. However, if phosphorylation or protein interaction has any effect on Tarp‟s 
ability to influence actin dynamics is not clearly understood. Post-translational 
modifications like phosphorylation, binding of lipid second messengers or calcium are 
intrinsic mechanism by which eukaryotic cell regulate the function of many proteins 
including cytoskeleton regulatory proteins. For examples, L-plastin loses its ability to 
bundle actin in its calcium bound conformation [418]. Synapsin, another actin bundling 
protein, shows reduce capacity to bundle actin when phosphorylated by calmodulin 
dependent kinase II [419]. Also, phosphorylation of filamin by CaM kinase II decreases 
filamin‟s actin cross linking activity [420]. We have previously shown that the ability of 
Tarp to interacts directly with actin is restricted to its c-terminal half that harbors actin 
binding domain. We also demonstrated that Tarp retains the ability to nucleate actin in 
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its phosphorylated form [412]. It will be interesting to determine if phosphorylation alters 
the actin bundling activity of Tarp. 
Collectively, our data demonstrates that Tarp harbors domains to distinctly bind 
globular and filamentous actin. Moreover, Tarps ability to bundle actin is independent of 
its nucleating capabilities. While Tarp from different chlamydial species shares low level 
of sequence homology, the actin nucleating ability is retained in all Tarp orthologs. If all 
Tarp orthologs also retain the ability to bundle actin and it‟s in vivo significance remains 
to be determined. 
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4.5 Figures 
 
 
 
 
 
Figure 19 Tarp deletion mutant demonstrate distinct actin binding and 
polymerization kinetics. 
 A) Schematics of Tarp proteins indicating the location of the actin binding domain (red 
box), the proline rich domain (blue box) and the tyrosine rich phosphorylation domain 
(green box). ∆ indicates amino acids deleted in mutant Tarp protein and numbers 
indicate amino acid positions encoded within the C.trachomatis tarP gene. Full length 
and mutant Tarp proteins were tagged with n-terminal GST tag and c-terminal histidine 
tag to purify recombinant protein for biochemical assays or with eGFP for 
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immunofluorescence assay. B) Extracts from HeLa cells were incubated with GST or 
GST fusions to wild-type or mutant Tarp and specifically bound proteins were resolved 
by SDS-PAGE and visualized by Coomassie blue staining (CB). Specifically, Tarp 
proteins harboring deletions in the phosphorylation domain (Δ phos), the proline rich 
oligomerization domain (Δ PRD) and the actin binding domain (Δ ABD) were tested. 
The HeLa lysate shown in the first lane represents 1% of the material used in the + 
lysate pulldown lanes. Samples identical to those shown in the Coomassie-stained gel 
were subject to immunoblotting with actin (α actin), phosphotyrosine (α Y-PO4) and 
peptide antisera specific for the proline rich (α PRD) and actin binding (α ABD) Tarp 
domains. Molecular mass of protein standards is in kDa. C) GST or GST Tarp fusion 
proteins described in B were incubated with 1μM monomeric pyrene-labeled actin. A 
Tarp-mediated increase in actin polymerization after the addition of polymerization 
buffer at 300 seconds was measured as arbitrary fluorescence intensity (Intensity (a.u.) 
over time (Time(s)) with excitation and emission wavelengths of 365 and 407 nm 
respectively.  GST and pyrene actin alone served as negative controls. D) eGFP-Tarp 
mutants colocalizes with filamentous actin in HeLa cells. Host cells expressing eGFP 
fusions of full length Tarp (Tarp), or deletion mutants lacking the phosphorylation 
domain (Tarp ∆ Phos), proline rich domain (Tarp ∆ PRD) or actin binding domain (Tarp 
∆ ABD ) were fixed and stained with Alexa fluor 568 conjugated phalloidin (actin). Host 
cells expressing eGFP alone or eGFP fusion of Tarp (1-748) were used as negative 
controls. 
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Figure 20 Tarp harbors an F-actin binding domain that is seperate from G-actin 
binding domain. 
 A) Extracts from HeLa cells were incubated with GST or GST fusions to the 100-aa 
fragment of Tarp containing the Tarp actin binding domain (ABD) L2 D726-S825 or the 
Tarp domain containing a similar sequence L2 P826-K940. Bound proteins were 
resolved by SDS-PAGE and visualized by Coomassie blue staining (CB). The HeLa 
lysate shown in the first lane represents 1% of the material used in the + lysate 
pulldown lanes. Samples identical to those shown in the Coomassie-stained gel were 
subject to immunoblotting with actin (α- actin). B) GST-TARP fusions were incubated 
with filamentous actin (F-actin) and isolated by ultracentrifugation. Protein supernatants 
and pellets were resolved by SDS/PAGE and visualized by Coomassie blue staining. 
GST-L2 D726-S825 and L2 P826-K940 precipitated with F-actin in the pellet fraction, as 
did the positive control protein (α- actinin). The GST control did not associate with the F-
actin pellet, and remained predominately in the supernatant. The actin shown in the first 
lane represents 2% of the material used in the + F actin lanes. Molecular mass of 
protein standards is in kDa. 
 
137 
 
 
 
Figure 21 Tarp ability to bind filamentous actin is dependent on two F-actin 
binding domain and one G-actin and F-actin binding domain. 
 Tarp deletion mutants expressed as either GST or eGFP fusions were examined for 
their ability to associate with filamentous actin. A)  Schematic of the GST- or eGFP- 
Tarp fusion proteins indicating the location of the actin binding domain (red box), the 
proline rich domain (blue box), the tyrosine rich phosphorylation domain (green boxes) 
and the newly characterized F-
indicates amino acids deleted in the mutant Tarp proteins and numbers indicate amino 
acid positions encoded within the C. trachomatis tarP gene. B) GST-Tarp fusions were 
incubated with filamentous actin (F-actin) and isolated by ultracentrifugation. Protein 
supernatants and pellets were resolved by SDS/PAGE and visualized by Coomassie 
blue staining.  GST-Tarp precipitated with F-actin in the pellet fraction, as did the 
positive control protein (α actinin). GST-Tarp fusions harboring deletions in ABD, FAB1 
and FAB2 domains precipitated with F-actin to a lesser extent as compared to GST-
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Tarp. The GST control did not associate with the F-actin pellet, and remained 
predominately in the supernatant. The actin shown in the first lane represents 2% of the 
material used in the + F actin lanes. Molecular mass of protein standards is in kDa. C) 
Tarp mutants ectopically expressed as enhanced green fluorescence protein fusions 
were examined for their ability to localize with actin filaments. Host cells expressing 
eGFP alone, eGFP fusions of full length Tarp (Tarp), or single deletion mutants lacking 
actin binding domain (Tarp ∆ ABD), double deletion mutant lacking actin binding domain 
and first F-actin binding domain (Tarp ∆ ABD ∆ FAB1) or triple deletion mutant lacking 
actin binding domain and both F-actin binding domains (Tarp ∆ ABD ∆ FAB1-2) were 
fixed and stained with Alexa fluor 568 conjugated phalloidin (actin). 
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Figure 22 Tarp bundels actin filaments. 
 A) Purified recombinant Tarp (GST removed) were incubated with filamentous actin (F-
actin) and isolated by low speed centrifugation. Protein supernatants and pellets were 
resolved by SDS/PAGE and visualized by coomassie blue staining. Tarp associated 
with actin filaments to form actin bundles which appeared in the pellet fraction, as did 
the positive actin bundling control protein (a-actinin). Neither the Tarp mutant, harboring 
three actin binding domain deletions, nor the GST control associate with actin, and 
remained predominately in the F-actin supernatant. Molecular mass of protein 
standards is in kDa. B) Similar experiment as described above was performed using 
Tarp mutant harboring proline rich domain deletion (Tarp ∆ PRD). Purified Tarp ∆ PRD 
(GST removed) retained the ability to cosediment with bundled F-actin. 
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4.6 Supplemental Information 
 
 
 
 
 
Figure 23 Tarp harbors a second site near its C-terminal that distinctly binds F-
actin. 
 A) Schematics showing series of truncated mutants of eGFP- Tarp ∆ ABD ∆ FAB1 
fusions having deletions at C-terminal domain at increments of approximately 12 amino 
acids. Phosphorylation domain and proline rich domain are represented by green and 
blue boxes respectively. Δ indicates amino acids deleted in the mutant Tarp proteins 
and numbers indicate amino acid positions encoded within the C. trachomatis tarP 
gene. B) eGFP- ∆ ABD ∆ FAB1 Tarp mutants as depicted above were ectopically 
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expressed in hela cells for their ability to form actin aggregates and colocalize with 
alexa fluor 568 conjugated phalloidin (actin). eGFP- ∆ ABD ∆ FAB1 Tarp mutants 
harboring deletions downstream to 966 amino acid of Tarp protein retained the ability to 
colocalize with phalloidin stained actin, whereas eGFP- ∆ ABD ∆ FAB1 Tarp mutants 
harboring deletions upstream to 966 amino acid of Tarp protein did not co-localize with 
phalloidin stained actin. 
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Figure 24 Tarp orthologs from C. trachomatis serovar A and D harbor domains 
that distinctly binds F-actin. 
 GST-A T940-D1040 and GST-D Q820-K940 from Chlamydia trachomatis serovar A 
and D, harboring domain that is similar to FAB1 of Chlamydia trachomatis L2 Tarp, 
were incubated with filamentous actin (F-actin) and isolated by ultracentrifugation. 
Protein supernatants and pellets were resolved by SDS/PAGE and visualized by 
Coomassie blue staining. GST- L2 P826-K940, GST-A T940-D1040 and GST-D Q820-
K940 precipitated with F-actin in the pellet fraction, as did the positive control protein (α-
actinin). The GST control did not associate with the F-actin pellet, and remained 
predominately in the supernatant. The actin shown in the first lane represents 2% of the 
material used in the + F actin lanes. Molecular mass of protein standards is in kDa. 
  
143 
 
CHAPTER FIVE: CONCLUSION 
5.1 Conclusion 
 
Intracellular bacterial pathogens represent a diverse group of microorganisms 
that have adapted to survive within eukaryotic host cells. Although these pathogens 
exhibit differences in their lifestyle and pathogenesis, they all share one common goal 
and that is to invade the host cells. To accomplish this goal, each organism is equipped 
with a unique set of proteins that have distinct functional capabilities which subvert the 
host cytoskeleton machinery. Unraveling the functions of these proteins and their 
interaction with the host will be the most critical step in developing new strategies to 
fight intracellular infections. My research was a step towards understanding the invasive 
strategies employed by two entirely different pathogens, L. monocytogenes and C. 
trachomatis. Below I will discuss the important findings of our research and its 
implications for future studies.  
PI 3-kinase is a ubiquitously expressed eukaryotic protein that plays a critical role 
in cell motility, survival, and proliferation [317, 318]. Increasing evidence is accumulating 
which suggests that the PI 3-kinase pathway is commonly exploited by many 
intracellular pathogens in promoting their own entry [365, 366, 368-371]; however, there 
have been no major efforts in elucidating the mechanisms by which PI 3-kinase activity 
can promote pathogen uptake. At best, the evidence has accumulated only in a 
piecemeal fashion. Using L. monocytogenes as a model, we performed a systematic 
RNAi-based screen to identify PI 3-kinase regulated host genes that might play a role in 
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pathogen uptake. Our study led to identification of at least 10 genes that are critical in 
Listeria entry which includes Rab5c, ARNO, ARAP2, GIT1, SWAP70, DAPP1, mTOR, 
PLC-γ, PDK1 and PKC-δ. In the future, it will be important to apply similar screening 
strategies on other pathogens whose entry also depends on the PI 3-kinase pathway. 
Such comparisons may lead to identification of certain key signaling proteins that are 
redundantly exploited by bacterial pathogens, and may serve as targets for adjuvant 
therapies.  
One of the most interesting outcomes of our screen was the identification of 
several PKC isoforms involved in Listeria entry. As we could confirm the role of PKC- δ 
in Listeria entry, we further pursued studying the role of PKC-δ. We confirmed the 
involvement of PKC-δ by showing that multiple siRNAs that deplete the PKC-δ protein 
also inhibit entry of Listeria. In addition, we also established that InlB treatment causes 
increased phosphorylation of PKC-δ, and that PKC-δ is needed for F-actin recruitment 
during InlB-mediated entry. Importantly, experiments with a PI 3-kinase inhibitor indicate 
that phosphorylation of PKC-δ caused by InlB is PI3-kinase-dependent (data not 
shown). Taken together, our results indicate that PKC-δ is needed for cyoskeletal 
changes and entry of Listeria, and suggest that PKC-δ acts downstream of PI 3-kinase.  
Among many different PKC isoforms, our screen included only PKC-δ, PKC-1/γ 
and PKC-δ because these are the only PKC isoforms that can be regulated directly by 
PIP3, a product of PI 3-kinase activity or by Grb2/Src kinase pathway [342, 421-423]. It 
is possible that in addition to atypical and novel PKCs, the conventional PKC (cPKC) 
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isoforms are also involved in internalization of Listeria. This consideration is based on 
the fact that Type IA PI 3-kinase (PI3K) can indirectly regulate cPKCs via activation of 
PDK1 or PLC-γ, which were also identified to play roles in Listeria entry based on our 
RNAi screen [424, 425]. PIP3 activates PDK1 by binding to its PH domain [426]. PDK1, 
in turn, controls the catalytically active conformation of PKCs by phosphorylation of a 
critical threonine residue in the activation loop [425]. Another way that PIP3 can 
regulate the activity of cPKC is through activation of Phospholipase C (PLC)-γ1 [424]. 
The end product of PLC-γ1, DAG, is a required cofactor for PKC activation and 
membrane recruitment [422]. In addition , IP3, a byproducts of PLC-γ1 activity cause 
fluxes of calcium, which is also an important cofactor for cPKC activity [427]. Thus it will 
be important in the future to study the role of conventional PKC isoforms in the entry of 
Listeria. In this regard, another interesting question will be the mechanism by which PI 
3-kinase regulates these PKC isoforms; via PDK1 mediated phosphorylation at critical 
serine/threonine residues, lipid messenger induced conformational changes, or both? In 
addition to their kinase activity, PKCs also possess protein-protein interaction motifs 
suggesting that PKCs might function as adaptor proteins [428]. It will also be important 
to know whether the kinase activity of PKCs is necessary for entry of Listeria or if their 
function involves protein-protein interaction. 
Upon activation, PKC mediates its effect by phosphorylation of various 
downstream target proteins, resulting in their activation and translocation to different 
cellular compartments [146]. Various substrates of PKCs include, but are not limited to; 
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proteins involved in phagocytosis, membrane trafficking, cell motility, migration, and 
cytoskeletal rearrangements [146]. Preliminary data suggest that PKC isoforms are 
involved in cytoskeletal rearrangements during InlB mediated entry, because siRNA 
inhibition of PKC-δ resulted in decreased F-actin recruitment around InlB coated 
microspheres. If other PKC isoforms also regulate F-actin changes, further analysis will 
be needed. We also observed recruitment of Myristoyleted Alanine rich C-Kinase 
Substrate (MARCKS), an actin cross-linking protein and a known target of PKCs, 
around InlB coated beads; however, we didn‟t confirm if a PKC isoform was responsible 
for recruitment of MARCKS. There are many other actin regulatory proteins that could 
also be the target of PKC activity in Listeria entry (see Table 4). Identification of PKC 
isoforms and their substrates involved in the internalization of Listeria will be helpful to 
understand the molecular mechanism by which type IA PI 3-kinase promotes bacterial 
entry. 
Rab5c is another interesting protein identified in our screen for Listeria entry. 
Rab5c could potentially control endocytic machinery or Rac dependent actin 
polymerization during Listeria entry [345, 347]. Rab5c is known to interact directly with 
both the p85α and p110 subunits of PI 3-kinase [147, 149, 346]. Such interaction 
stimulates intrinsic Rab GTPase activity which causes inactivation of Rab by GTP 
hydrolysis. The other potential pathway that controls Rab5c activity is the p38 map 
kinase pathway, which stimulates GDP/GTP exchange by inhibiting the activity of the 
GDP dissociation inhibitor (GDI)[429]. Interestingly, Rab5c/Rac induced membrane 
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ruffling following HGF stimulation of the Met receptor in HeLa cells was found to be 
independent of the PI 3-kinase pathway[347]. Moreover, Rab5c has also been shown to 
regulate endocytic trafficking via the p38 map kinase pathway[429]. Since components 
of the endocytic pathway are involved in Listeria entry, the interesting question will be to 
know if Rab5c activity is regulated via the PI 3-kinase pathway, the p38 Map kinase 
pathway, or both given the fact that both pathways are active in Listeria entry [142, 158, 
430]. 
Recently, the role of β1 and β3 integrin receptors have been implicated in InlB 
mediated entry as antibody mediated blocking of integrin receptors abrogated Listeria 
entry[355]. Also, incubation of HeLa cells with a ΔInlA mutant Listeria strain resulted in 
increased Focal adhesion kinase (FAK) phosphorylation, suggesting a possible 
contribution of integrin/FAK signaling in InlB mediated entry [355]. Interestingly, FAK 
and integrin linked kinases (ILK) were found to be dispensable for Listeria entry in our 
screen, and how integrin promotes InlB mediated entry is not yet known. Recently, the 
role of the β1 integrin receptor in PI 3-kinase dependent entry of the vaccinia virus has 
been demonstrated [431]. There is also a considerable amount of evidence that 
suggests cross talk between integrin and growth factor receptors, including Met [432, 
433]. In the future, it will be interesting to test the contribution of the integrin receptor on 
Met/PI 3-kinase activation during entry of Listeria.  
 Signaling via the PI 3-kinase pathway is also implicated in the developmental 
cycle of many chlamydial species. For example, it plays a critical role in invasion of C. 
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pnuemoniae and C. caviae [298, 366]. Evidence is also accumulating that indicates PI 
3-kinase signaling plays a role in post entry events of C. trachomatis and C. pneumonia 
[258, 366]. Despite such significant involvement, efforts are lacking to dissect the 
components of the PI 3-kinase pathways involved in chlamydial biology. The RNAi 
screening strategy we employed to dissect out molecular mechanisms of Listeria entry 
has proven to be a valuable tool. Of note, the library we created comprises proteins 
such as AKT, mTor, PDK1, and several AGC kinases that are known to play a 
multifunctional role in many physiological processes, including cell motility, survival, and 
lipid metabolism. It is likely that some of these components are also usurped by different 
chlamydial species for either invasion or intracellular development. Employing a similar 
RNAi screen, as in the case of Listeria, will significantly enhance our understanding of 
the role PI 3-Kinase plays in chlamydial biology.   
Unlike Listeria, chlamydial species have conserved genes for the type III 
secretion apparatus [224, 240]. Chlamydia uses this needle like apparatus to deliver 
effector proteins that play important roles in various phases of the chlamydial 
development cycle. Tarp is one such effector protein delivered by chlamydia into the 
host cytoplasm prior to its invasion [243]. Tarp has the capability to nucleate actin, 
which was found to be essential for chlamydia entry [64, 307]. Thus, the most 
distinguishing difference between Listeria and Chlamydia invasion is that the 
cytoskeletal rearrangements necessary for Listeria invasion are dependent on a host 
cell actin nucleator, the Arp2/3 complex[150]; whereas, the Chlamydia invasion requires 
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the activity of both the Arp2/3 complex and the Tarp [296, 307]. Why a bacterium like 
Chlamydia needs a host cell actin nucleator when it has one of its own is unknown. 
Evidence suggests that certain bacteria like entero-invasive E. coli require prior 
cytoskeletal rearrangements for efficient delivery of effector proteins [402]. However, 
this does not seem to be the case for Chlamydia, as delivery of the effector protein, 
Tarp, was not hampered in host cells that were inhibited for Arp2/3 complex activity. 
Using an in vitro actin polymerization assay, we provided evidence suggesting that Tarp 
and the Arp2/3 complex co-operate to polymerize actin. Use of multiple nucleators, and 
their cooperative activity, might be a common strategy for obligate intracellular 
organisms like Chlamydia to promote efficient entry, as their survival is completely 
dependent on their ability to invade the host cell. This can be reflected by the fact that 
the efficiency of Chlamydia to invade host cells is at least 10 times greater than Listeria, 
which can survive in an extracellular environment [294, 434].  
The molecular mechanism of the Arp2/3 complex activation during chlamydial 
entry is the most important unresolved question in its biology. Generally, the activation 
of the Arp2/3 complex during bacterial entry is a function of either adhesin/receptor 
interactions or effector proteins. Previously, the role of phosphorylated Tarp was 
implicated in the Arp2/3 complex activation [296]. However, we provided evidence 
against the ability of Tarp to activate the Arp2/3 complex. We demonstrated that neither 
Tarp acts as a nucleation promoting factor, nor does it initiate intracellular signaling 
events responsible for activation of the Arp2/3 complex. Whether Chlamydia secretes 
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some unknown effector protein or activates host surface receptors to cause the Arp2/3 
complex activation will be the most interesting scientific pursuit in the future. Several 
reports have been published which claim the role of different host receptors involved in 
chlamydial entry, including PDGF, FGF, CFTR, and PDI [237-239, 291]. However, the 
inhibition of main signaling pathways downstream to these receptors, including the PI 3-
kinase and MAP kinase pathways, had no effect on C. trachomatis entry. This suggests 
that some other independent pathway might be responsible for activation of the Arp2/3 
complex. Recently, IQGAP, an adaptor protein that can link growth factor receptors 
directly to N-WASP/Arp2/3 mediated cytoskeleton changes, has been identified [409]. 
This might explain the activation of the Arp2/3 complex during chlamydial entry; 
however, such claims need further scientific evaluations. 
The most significant finding of our research on Chlamydia was the identification 
of two F-actin binding (FAB) domains in the c-terminal half of C. trachomatis L2 Tarp. 
Apart from Tarp‟s ability to nucleate actin, the presence of FAB domains impart Tarp 
with capabilities to bundle actin, at least in an in vitro assay. The function of Tarp to 
nucleate actin was found to be essential for chlamydial entry as microinjection of host 
cells with antibodies targeting the ABD abrogated entry [307]. Whether the bundling 
activity of Tarp is also essential for entry of Chlamydia is yet to be studied. Recently, a 
Salmonella effector protein, SipC, was found to possess actin nucleation and bundling 
activity similar to Tarp [415]. In vivo studies using SipC mutant strains of Salmonella 
demonstrated that both nucleation and bundling activity of SipC are essential for 
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efficient Salmonella invasion [8]. Similar studies in Chlamydia would require generation 
of mutant strains harboring in frame deletions of the FAB domains. However, unlike 
Salmonella or other microorganisms for which we have established scientific methods of 
genetic manipulations, the transformation strategies for Chlamydia are in its infancy 
[435]. Therefore it has not been possible to target any single gene of the chlamydial 
genome. Nonetheless, many labs, including ours, are focusing on this aspect of 
chlamydial research. We have developed shuttle vectors that can be transformed into 
Chlamydia and are currently directing our resources to transform Chlamydia with a 
vector harboring different domain deletion mutants of Tarp, including the FAB domains. 
Another strategy that could also be employed for studying the function of the FAB 
domains is to functionally target the domains using antibodies specific to these domain. 
Currently, there are no monoclonal antibodies that can specifically recognize either FAB 
domain of Tarp. Thus functional inhibition of the FAB domains would require generation 
of FAB specific antibodies.  
Upon genomic analysis, different chlamydial species share 99% sequence 
identity [281, 305]. The differences in pathogenesis of chlamydial infections, such as 
host specificity and tissue tropism, are believed to be due to variations within the genes 
representing 1% of the genome. Tarp is one such gene that exhibits high level of 
variability within different chlamydial species and serovars; however, certain domains, 
like the actin binding domain and proline rich domain, are found to be conserved among 
all Tarp orthologs [306]. Thus, these domains represent the important aspects of 
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chlamydial biology as confirmed previously by in vivo analysis. Interestingly, the 
secondary structure analysis of all Tarp orthologs also reveals the presence of α-helices 
similar to the FAB1 and FAB2 domains found in L2 Tarp. Moreover, Tarp orthologs 
within the trachoma group share 100% sequence homology for FAB1 and FAB2 
domains (see figure 25). While our study confirmed the significance of the FAB 
domains in L2 Tarp to bundle F-actin, it will be important in the future to analyze if such 
capabilities are retained in different Tarp orthologs. Conservation of Tarp‟s function 
would point towards the importance of FAB domains in the pathogenesis and overall 
biology of Chlamydia. 
Unlike the PRD, ABD, and potentially the FAB domains, which seem to be 
conserved among different Tarp orthologs, the PhosD is present only in Tarp orthologs 
that belong to the trachoma group of chlamydial species [306]. So far, the role of the 
PhosD in Tarp has remained elusive in chlamydial biology. Previous observations have 
linked the PhosD with cytoskeleton regulation during invasion, but our recent evidence 
has refuted such claims. Since Tarp remains bound to the inclusion membrane, it will be 
interesting to know if the PhosD plays a significant role in intracellular development of 
C. trachomatis [243]. Recent evidence suggests that the PhosD can serve as a hub for 
host signaling proteins. Biochemical in vitro analysis revealed the ability of 
phosphorylated Tarp to bind several SH2 domain containing proteins including PI 3-
kinase and adaptor proteins like SHC1 and Nck1/2 [312, 398]. The SHC1 adaptor 
protein linked MAPK/ERK pathway is critical for host cell survival following chlamydial 
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infection [398]. Moreover, unpublished data from our lab also implicates the important 
role of PI 3-kinase/AKT signaling in inclusion development. Whether Tarp or some other 
chlamydial proteins initiate such signaling events in vivo is not yet known. One possible 
approach to determine the effects of Tarp phosphorylation would be to transfect full 
length and phosphorylation domain deletion mutants of Tarp in eukaryotic cell lines to 
monitor the effects on activation of key signaling molecules such as AKT, ERK1/2, etc. 
However, confirmatory evidence would require genetic approaches to study the effects 
of the PhosD deletion on overall development of C. trachomatis.  
Certainly, Tarp seems to be one of the most critical virulent genes acquired by 
pathogenic chlamydial species. Current evidence indicates the role of Tarp in many 
different aspects of chlamydial biology including invasion, intracellular development, and 
pathogenesis. While I am curious to learn more about the functions of Tarp, I will 
desperately await the day we know „the life of Chlamydia without Tarp‟. 
In conclusion, based on the findings from this research we are proposing the 
revised models of Listeria monocytogenes and Chlamydia trachomatis entry (See 
figure 26 and 27). I strongly believe that the work done in thesis will serve as a frame 
work for future research to extend our knowledge about the entry mechanisms used by 
these organisms. With this knowledge I hope we will be able to develop strategies in 
preventing infections from these organisms. 
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5.2 Figures 
 
Table 4 Known downstream targets of PKC 
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Figure 25 Putative FAB domains in C. trachomatis serovar A and D, C. caviae and 
C. muridarum. 
 Secondary structure analysis was done to identify the presence of additional alpha 
helices in C-terminal domain of Tarp orthologs except for the known actin binding 
domains. Number represents the amino acid position. Amino acids highlighted in pink 
box represent alpha helix on secondary structure analysis. Sequence alignment of Tarp 
orthologs C. trachomatis serovar L2, A and D, C. caviae and C. muridarum was done 
using Clustal W. version 1.82, multiple-sequence alignment software (http:// 
www.ebi.ac.uk/clustalw). Note the presence of conserved FAB1 and FAB2 domain with 
100% sequence homology within Tarp orthologs from C. trachomatis serovar L2, A and 
D. Alpha helixes are also identified in C. caviae and C. muridarum Tarp at the 
corresponding locations with ~65% sequence homology to FAB1 and FAB2 in C. 
trachomatis L2 Tarp. 
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Figure 26 Potential mechanism of control of Listeria entry by type 1A PI 3-kinase. 
 Infection of human cells with Listeria expressing InlB results in activation of the host 
Met receptor and of type IA PI 3-kinase [61, 130, 142]. The RNAi-based screen 
described in this work led to the identification of nine human proteins involved in PI 3-
kinase signaling that play important roles in Listeria entry. Based on biological functions 
of these nine proteins reported in the scientific literature, a diagram was constructed 
depicting some of the possible ways that the host proteins could participate in bacterial 
uptake. Rab5c, a protein that interacts with regulatory and catalytic subunits of type IA 
PI 3-kinase, could promote Listeria entry by controlling the host endocytic machinery 
[158, 345]. ARNO, an activator of Arf GTPases that binds directly to the PI 3-kinase 
product PI(3,4,5)P3, might help maintain proper plasma membrane levels of integrins, a 
class of receptor recently found to enhance InlB-mediated entry [355]. The 
serine/threonine kinase PKC- Listeria internalization by controlling the 
actin cytoskeleton and/or delivery of membrane through exocytosis (6, 48, 67). PKC-
is indirectly regulated by PI 3-kinase through the master kinase PDK1, which is a direct 
target of PI(3,4,5)P3 [338]. mTor, a serine/threonine kinase indirectly controlled by type 
IA PI 3-kinase, might promote bacterial uptake through activation of the host proteins 
Rac1  and/or PKC-
157 
 
proteins identified in the RNAi screen have the potential to control Listeria entry though 
activation of Rac1 GTPase. These proteins, SWAP70, DAPP1, and GIT1, each bind 
directly to PI(3,4,5)P3. SWAP70 is a direct activator of Rac1, and stimulates nucleotide 
exchange on the GTPase [331]. DAPP1 and GIT1 lack recognizable guanine nucleotide 
exchange factor (GEF) domains, and likely indirectly activate Rac1. In addition to being 
an indirect activator of Rac1, GIT1 is also a GTPase Activating Protein (GAP) that 
inhibits Arf6 GTPase [351]. Along with ARAP2, another Arf6 GAP needed for Listeria 
entry [323], GIT1 might restrain activation of Arf6, which would otherwise interfere with 
bacterial uptake. Constitutively activated Arf6 alleles inhibit Listeria internalization [323], 
and also induce the redistribution of cholesterol from the plasma membrane to internal 
membrane compartments [350]. Since plasma membrane cholesterol is critical for InlB-
mediated entry, it is possible that GIT1 and/or ARAP2 promote Listeria uptake by 
maintaining proper localization of cholesterol and/or other lipids [323]. 
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Figure 27 Revised model for entry of C. trachomatis in non-phagocytic cells. 
 EB translocate Tarp into host cell cytoplasm. Tarp, via its actin binding domain (red 
box) and proline rich oligomerization domain (blue box), directly polymerizes actin to 
generate linear F-actin. Tarp via its FAB domains binds and bundles F-actin. Interaction 
of EB with host cell surface receptor causes activation of Arp2/3 complex. Arp2/3 
complex uses linear bundles of actin filaments to form complex array of actin network to 
promote efficient uptake of EBs into non-phagocytic cells. 
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